Stent-valves for valve replacement and associated methods and systems for surgery

Information

  • Patent Grant
  • 10265167
  • Patent Number
    10,265,167
  • Date Filed
    Wednesday, January 18, 2017
    7 years ago
  • Date Issued
    Tuesday, April 23, 2019
    4 years ago
Abstract
Stent-valves (e.g., single-stent-valves and double-stent-valves), associated methods and systems for their delivery via minimally-invasive surgery, and guide-wire compatible closure devices for sealing access orifices are provided.
Description
FIELD OF THE INVENTION

Embodiments of the present invention relate to stent-valves, associated methods and systems for their delivery via minimally-invasive surgery, and guide-wire compatible closure devices for sealing access orifices.


BACKGROUND OF THE INVENTION

Conventional approaches for cardiac valve replacement require the cutting of a relatively large opening in the patient's sternum (“sternotomy”) or thoracic cavity (“thoracotomy”) in order to allow the surgeon to access the patient's heart. Additionally, these approaches require arrest of the patient's heart and a cardiopulmonary bypass (i.e., use of a heart-lung bypass machine to oxygenate and circulate the patient's blood). Despite their invasiveness, these surgical approaches may be reasonably safe for a first intervention. However, tissue adherences resulting from the first surgery may increase the risks (e.g., death) associated with subsequent valve replacement surgeries. See Akins et al., “Risk of Reoperative Valve Replacement for Failed Mitral and Aortic Bioprostheses”, Ann Thorac Sag 1998; 65:1545-52; and Weerasinghe et al., “First Redo Heart Valve Replacement-A 10-Year Analysis”, Circulation 1999; 99:655-658; each of which is incorporated by reference herein in its entirety.


Synthetic valves and biological valves have been used for cardiac valve replacement with varying results. Synthetic valves rarely fail but require life-long anti-coagulant treatment to prevent blood from clotting (thrombosis) in and around the replacement valve. Such anti-coagulant treatment significantly limits patients' activities and can cause various other complications. Biological valves do not require such anti-coagulation treatment but typically fail within 10-15 years. Thus, to limit the need for and risks associated with re-operation on failed biological valves, traditionally only patients with less than about 10-15 years to live have received biological valve replacements. Patients with longer life expectancies have received synthetic valves and anti-coagulant treatment.


Attempts have been made to develop less-invasive surgical methods for cardiac valve replacement. These surgical methods, referred to as percutaneous heart valve replacement therapies (PHVT), use a catheter to deliver a replacement valve to an implantation site using the patient's vascular system. These PHVT attempts have various shortcomings, including their inability to ensure proper positioning and stability of the replacement valve within the patient's body.


Conventional closure devices for closing access orifices are also lacking in several respects, including the looseness of their fit which can cause bleeding after surgery. These closure devices also lack a central lumen, which renders them incompatible with guide wire delivery systems. One such conventional closure device is described in Malgorzata Pawelec-Wojtalik, “Closure of left ventricle perforation with the use of muscular VSD occluder”, European Journal of Cardio-Thoracic Surgery 27 (2005) 714-716, which is incorporated by reference herein in its entirety.


In view of the foregoing, it would be desirable to provide improved methods, systems, and devices for cardiac valve replacement.


SUMMARY OF THE INVENTION

Some embodiments of the present invention are directed to systems, methods, and devices for cardiac valve replacement. For example, these methods, systems, and devices may be applicable to the full range of cardiac-valve therapies including the replacement of failed aortic, mitral, tricuspid, and pulmonary valves. In some embodiments, the present invention may facilitate a surgical approach whereby surgery is performed on a beating heart without the need for an open-chest cavity and heart-lung bypass. This minimally-invasive surgical approach may reduce the risks associated with replacing a failed native valve in the first instance, as well as the risks associated with secondary or subsequent surgeries to replace failed artificial (e.g., biological or synthetic) valves.


Stent-valves according to some embodiments of the present invention may include a valve component and at least one stent component. The valve component may include a biological or synthetic (e.g., mechanical) valve and/or any other suitable material(s). The stent component may include a first section (e.g., proximal section), a second section configured to house the valve component, and a third section (e.g., distal section). The stent and valve components may be capable of at least two configurations: a collapsed configuration (e.g., during delivery) and an expanded configuration (e.g., after implantation).


In some embodiments, the first section of the stent valve may include a fixation element. Such a fixation element may include, for example, an annular groove for securing the stent-valve in place at an implantation site. When the stent-valve includes a single stent (“single-stent-valve”), the annular groove may be configured to receive the annulus of the valve in need of replacement. When the stent-valve includes two stents (“double-stent-valve”), the annular groove of the first stent component may be configured for matable attachment to a complimentary annular projection of a second stent component (i.e., a positioning stent). In turn, the second stent component may be anchored at the implantation site, for example, to the valve in need of replacement and/or adjoining structures.


Alternatively or additionally, in some embodiments the third section of the stent component may include at least one attachment element. Each attachment element of the stent-valve may include, for example, a geometrical opening (e.g., circular or ovular), hook, or strap configured for removable attachment to a complimentary structure of a delivery device. In addition, each attachment element may correspond to all or a portion of a commissural post, to which a commissure between two valve leaflets may be attached. The attachment element(s) may allow the stent-valve to be partially expanded within a patient's body while the stent-valve remains attached to the delivery device. This may allow the stent-valve to be returned to a collapsed configuration and repositioned within the patient's body when it is determined that fully expanding the stent-valve would cause the stent-valve to be installed incorrectly. Alternatively or additionally, this may allow the stent-valve to be returned to the collapsed configuration and removed from the patient's body when it is determined that the stent-valve is not functioning properly (e.g., not permitting sufficient flow). In some embodiments, the stent-valve may include one attachment element. In other embodiments, the stent-valve may include at least two, three, six, or any other suitable number of attachment elements. In some embodiments, the fully-expanded stent diameter in the region of the attachment element(s) may be smaller than the diameter of the region that houses an associated valve. This may reduce the risk of injury to the patient's body (e.g., perforation of the aorta) from the attachment elements and/or make it easier to affix the attachment elements to the complimentary structure of the delivery device.


In some embodiments, the stent component of the stent-valve may include a lattice structure with a plurality of cells. The lattice structure may be formed from, for example, a shape-memory alloy such as nitinol or any other suitable material(s). The cells in the lattice structure may be most densely populated in the section of the stent component that includes the fixation element. This may provide added support to the fixation element and increase the stability of the stent-valve. In some embodiments, the lattice structure may form at least one elongate stein (e.g., commissural post) that extends distally along the stent component towards the at least one attachment element. The at least one stem may connect directly to the at least one attachment element. Alternatively, the lattice structure may form at least one supporting element for connecting the at least one stem to the at least one attachment element. In some embodiments, all of the cells in the lattice structure may be closed cells, which may facilitate recapture of the stent-valve from the partially-expanded configuration to the collapsed configuration.


Still other embodiments of the present invention are directed to a method for replacing a valve. A stent-valve is provided that includes a stent component with an annular groove, and the stent-valve is secured axially to an annulus of the valve in need of replacement. In some embodiments, providing a stent-valve may include suturing a valve component to the stent component. Alternatively or additionally, providing a stent-valve may include expanding a valve component within the stent component in order to form a friction fitting. In some embodiments, providing a stent-valve may include securing a valve component to the stent component with a hook-and-loop (e.g., VELCRO®) fastening system.


In other embodiments of the present invention, a method for replacing a valve is provided whereby a first stent component that includes an annular element is implanted such that at least a portion of the first stent component is housed within a valve in need of replacement. A stent-valve that includes a second stent component is positioned within the first stent component by matably attaching a complimentary annular element of the second stent component to the annular element of the first stent component.


In still other embodiments of the present invention, a stent-valve delivery system is provided. A first assembly is provided that includes an outer sheath and a guide wire tubing. The delivery system also includes a second assembly including a stent holder configured for removable attachment to at least one attachment element of a stent-valve. The stent-valve may be positioned over the guide wire of the first assembly. The first assembly and the second assembly may be configured for relative movement with respect to one another in order to transition from a closed position to an open position. In the closed position, the outer sheath may encompass the stent-valve still attached to the stent holder and thus constrain expansion of the stent-valve. In the open position, the outer sheath may not constrain expansion of the stent-valve and thus the stent-valve may detach from the stent holder and expand to a fully expanded configuration.


In some embodiments, the first assembly and the second assembly may be configured to transition from the closed position, to a partially-open position, to the open position. In the partially-open position, the stent-valve may expand partially but not detach from the stent holder because the outer sheath may still encompass the at least one attachment element of the stent-valve and the stent holder. When the stent-valve is in the partially-expanded configuration, it may be determined whether the stent-valve will be positioned correctly if the stent-valve is expanded to the fully expanded configuration. Alternatively or additionally, the functionality of the stent-valve may be tested (e.g., to determine whether the stent-valve will permit sufficient blood-flow) when the stent-valve is in the partially-expanded configuration.


In some embodiments, the stent-valve delivery system may include at least one balloon (e.g., proximal to the stent-valve or other stent to be delivered) configured to cause expansion of the stent-valve or positioning stent upon inflation of the at least one balloon.


In some embodiments, the stent-valve delivery system may include a push handle that causes the relative movement of the first assembly and the second assembly. Alternatively, the stent-valve delivery system may include a screw mechanism for translating rotational movement of a handle into the relative movement of the first assembly and the second assembly.


In some embodiments, the stent-valve delivery system may include an integrated introducer within which the first assembly and the second assembly are positioned during delivery of the stent-valve to an implantation site. The integrated introducer may be configured to remain within a patient's body even after the first assembly and the second assembly are removed, for example, to allow for the introduction of an occluder.


In some embodiments, after expansion of the stent-valve to the fully expanded configuration, the delivery system may be configured to return to the closed position by passing the second assembly through the stent-valve towards a distal end of the first assembly.


Still other embodiments of the present invention are directed to a method for delivering a stent-valve to an implantation site whereby the stent-valve is removably attached to a delivery device and the stent-valve is delivered to the implantation site in a collapsed configuration. The stent-valve may be partially expanded while maintaining the stent-valve attached to the delivery device. A determination with respect to the stent-valve may be made when the stent-valve is in the partially-expanded configuration. When the determination yields a positive response, the stent-valve may be expanded to its fully expanded configuration by causing the stent-valve to detach from the delivery device.


In one particular embodiment, it may be determined whether the stent-valve is positioned correctly at the implantation site. The stent-valve may be returned to the collapsed configuration and repositioned when the stent-valve is not positioned correctly at the implantation site.


Alternatively or additionally, it may be determined whether a valve component of the stent-valve is functioning properly, for example, by testing whether the valve component will permit sufficient blood-flow. The stent-valve may be returned to the collapsed configuration and removed from a patient's body when the stent-valve is not functioning properly.


In some embodiments, delivering the stent-valve to the implantation site may include delivering the stent-valve to the heart for replacement of a cardiac valve. The delivery may include accessing a patient's body through an intercostal space (e.g., fifth intercostal space) and penetrating the left ventricle at the apex of the heart.


In still other embodiments of the present invention, an occluder for sealing an orifice in tissue is provided. The occluder may include a first portion capable of expansion from a collapsed configuration on a luminal side of the orifice to an expanded configuration. The occluder also includes a second portion capable of expansion from a collapsed configuration to an expanded configuration on a side of the orifice opposite to the luminal side. The first portion and the second portion may form a central, hollow channel for housing a guide wire.


In some embodiments, the occluder may include a connector for connecting the occluder to a catheter. For example, the connector may include a hollow screw mechanism for connecting to a threaded catheter. The occluder may be housed by a second catheter for delivery to the tissue orifice.


In some embodiments, the top portion of the occluder may include a channel sealing mechanism for preventing blood-flow from the luminal side of the tissue orifice. For example, the channel sealing mechanism may include a membrane, foam, and/or a valve. Suitable examples of foam and/or membranous materials include polyurethane and gelatin.


In some embodiments, the top portion of the occluder may include a first material and the bottom portion of the occluder may include a second material, where the second material may be coarser than the first material. This may facilitate the formation of scar tissue on the outer portion and speed the heeling process. For example, the first and/or second materials may include felt(s) and/or velour(s) made from Teflon, Dacron, polyurethane, polydioxanone, polyhydroxybutyrate, and/or other material.


In other embodiments of the present invention, a method for sealing an orifice in tissue is provided whereby an expandable and collapsible occlusion device is connected to a first catheter. The occlusion device may be inserted into a second catheter in a collapsed condition. The first catheter and a central channel of the occlusion device may receive a guide wire. The second catheter may be positioned in the orifice, such that a first end of the second catheter is positioned on a luminal side of the orifice. Relative movement between the collapsed occlusion device and the second catheter may be caused in order to move the occlusion device out of the second catheter. Upon the occlusion device emerging from the first end of the second catheter, a first portion of the occlusion device may expand on the luminal side of the orifice. Upon the occlusion device being completely emerged from the second catheter, a second portion of the occlusion device may expand.





BRIEF DESCRIPTION OF THE DRAWINGS

For a better understanding of the present invention, reference is made to the following description, taken in conjunction with the accompanying drawings, in which like reference characters refer to like parts throughout, and in which:



FIG. 1A shows a valve component in an expanded configuration according to some embodiments of the present invention;



FIG. 1B shows a valve component in a collapsed configuration according to some embodiments of the present invention;



FIG. 2A shows a stent component in an expanded configuration according to some embodiments of the present invention;



FIG. 2B shows a single-stent-valve, that includes a stent component and a valve component, in an expanded configuration according to some embodiments of the present invention;



FIG. 2C shows a single-stent-valve a collapsed configuration according to some embodiments of the present invention;



FIG. 3A shows a stent component in an expanded configuration according to some embodiments of the present invention;



FIG. 3B shows a stent component in a collapsed configuration according to some embodiments of the present invention;



FIG. 4 shows a double-stent-valve, that includes two stent components and a valve component, in an expanded configuration according to some embodiments of the present invention;



FIGS. 5A-7B illustrate the use of a single-stent-valve to replace a failed biological (artificial) valve according to some embodiments of the present invention;



FIGS. 8A and 8B show a stent component that includes attachment elements for securing the stent to a delivery device and fixation elements for securing the stent at the implantation site according to some embodiments of the present invention;



FIG. 8C shows a stent component having a diameter in the region of the attachment element(s) that is smaller than the diameter of a stent region that houses an associated valve, according to some embodiments of the present invention;



FIG. 8D shows a stent component that includes independently bendable element(s) for use in positioning/securing the stent to the geometry/topology at an implantation site according to some embodiments of the present invention;



FIG. 8E shows a stent component that includes locking elements in a crown configuration and a fixation element for securing the stent at an implantation site according to some embodiments of the present invention;



FIG. 8F shows a stent component that includes multiple struts for carrying a valve component more closely to a region of the stent component that includes attachment element(s) for attaching the stent component to a delivery device;



FIGS. 9A-16 show additional embodiments of stent components that include attachment elements for securing the stent to a delivery device and/or fixation elements for securing the stent at the implantation site according to the present invention;



FIGS. 17/18, 19, and 20 show additional examples of double-stent-valves according to some embodiments of the present invention;



FIG. 21A shows a stent-valve in the shape of an opposed double crown according to some embodiments of the present invention;



FIGS. 21B-E show views of a double-conical stent in accordance with some embodiments of the present invention;



FIGS. 22A-22D show a delivery system for delivering a self-expanding stent-valve to an implantation site according to some embodiments of the present invention;



FIGS. 23A-23D show a delivery system with inflatable balloon(s) according to some embodiments of the present invention;



FIGS. 24A-24D show a delivery system having a proximal outer shaft with an increased diameter according to some embodiments of the present invention;



FIGS. 25A-25C show a delivery system with inflatable balloon(s) according to some embodiments of the present invention;



FIGS. 26A-26C show a delivery system with an integrated introducer according to some embodiments of the present invention;



FIG. 27 is a flowchart of illustrative stages involved in replacing a failed native or artificial valve according to some embodiments of the present invention;



FIGS. 28A-C illustrate the replacement of a failed valve through the use of a delivery system according to some embodiments of the present invention;



FIGS. 29A and 29B show a guide wire compatible occluder for sealing an access orifice according to some embodiments of the present invention;



FIG. 30 shows a guide wire for guiding the delivery of an occluder and/or stent-valve according to some embodiments of the present invention;



FIG. 31 shows a threaded catheter for attachment to and use in positioning an occluder according to some embodiments of the present invention;



FIGS. 32A and 32B show a delivery system for an occluder according to some embodiments of the present invention; and



FIGS. 33A and 33B show an occluder positioned within an access orifice according to some embodiments of the present invention.





DETAILED DESCRIPTION OF THE INVENTION


FIGS. 1A-3B show components 100, 200, and 300 for use in replacing, for example, a failed (e.g., degenerated) aortic valve, mitral valve, or pulmonary cardiac valve (e.g., in a pediatric patient) in accordance with some embodiments of the present invention. More particularly, FIGS. 1A and 1B show a valve component 100. FIGS. 2A-2C show a stent component 200 for housing valve component 100. FIGS. 3A and 3B show a stent component 300 for housing stent component 200 and valve component 100. A device that includes components 100 and 200 may be referred to as a single-stent-valve. A device that additionally includes component 300 may be referred to as a double-stent-valve.



FIG. 4 shows a double-stent-valve 400 that includes valve component 100, stent component 200, and stent component 300 in accordance with some embodiments of the present invention. Double-stent-valve 400 may replace a failed native or artificial valve. As used herein, a “native valve” refers to a valve naturally present within a patient's body. A failed native valve may be, for example, a stenotic valve. An “artificial valve” refers to a biological or synthetic (e.g., mechanical) valve introduced into the patient's body through surgery. The implantation site for a device 400 (or other replacement valve) typically includes at least a part of the area within the failed valve and/or along at least a portion of adjacent structure(s). For example, to replace a failed aortic valve, device 400 may be implanted within the patient's body such that portion 402 of the device is positioned substantially entirely within the failed aortic valve. Portion 404 of device 400 may extend along at least a portion of the aorta. Portion 406 of device 400 may extend into at least a portion of the left ventricle of the patient's heart.


Double-stent-valve 400 may be delivered to the implantation site using any suitable delivery approach. In some embodiments of the present invention, device 400 may be substantially entirely assembled from components 100, 200, and 300 outside the patient's body before device 400 is delivered to the implantation site. In other embodiments of the present invention, components 100, 200 and 300 of device 400 may be delivered to the implantation site separately in multiple steps. For example, stent component 300 may be delivered and installed at the implantation site, followed by the delivery and installation of stent component 200 and valve component 100 in one or more separate steps. In one embodiment, components 100 and 200 may be assembled outside the patient's body and then delivered and installed within component 300 at the same time. In another embodiment, stent component 200 may be delivered and installed within stent component 300, followed by the delivery and installation of valve component 100 in a separate step. Additional embodiments of double-stent-valves are described in connection with FIGS. 17-20.


In some embodiments of the present invention, a single-stent-valve (FIG. 2B) that includes valve component 100 and stent component 200 (but not stent component 300) may be used to replace a failed native or artificial valve. For example, in one particular embodiment, the single-stent-valve may replace a failed biological valve introduced to a patient's body during a prior valve replacement surgery. Thus, the surgery involving the single-stent-valve shown in FIG. 2B may be a secondary or subsequent valve replacement surgery. Although in this embodiment no new stent component 300 may be introduced to the patient's body, the single-stent-valve including components 100 and 200 may be housed by a stent and/or valve remaining at the implantation site from the prior valve replacement surgery. In some embodiments, at least a portion of the stent and/or valve from the prior surgery may be removed before the single-stent-valve is installed at the implantation site. Additional details regarding the replacement of a failed biological valve with a single-stent-valve are described in connection with FIGS. 5A-7B.


In some embodiments of the present invention, valve component 100 may be flexible and collapsible such that it can be collapsed, for example, during delivery via a catheter to the implantation site. Various embodiments of delivery systems and surgical approaches for minimally-invasive surgery are described below in connection with FIGS. 22A-26C. Upon delivery, the valve component may be at least partially expanded. FIG. 1A is a perspective view of valve component 100 in an expanded configuration. FIG. 1B is a perspective view of valve component 100 in a collapsed configuration. As used herein, “collapsed configuration” and “expanded configuration” refer to a relative difference in, for example, the diameter and/or any other physical characteristic(s) of a component (e.g., length, width). For example, the collapsed valve component shown in FIG. 1B has an reduced diameter and may or may not have a longer length than the expanded valve component shown in FIG. 1A.


Valve component 100 may include a biological material (e.g., tanned, untanned, heterologous or autologous), non-biological material, a synthetic material (e.g., polymer(s) such as polyurethane and/or silicon(es)), or a combination thereof. In some embodiments, valve component 100 may include preserved biological tissue such as, for example, human tissue (e.g., homografts, autografts of valve tissue) or animal tissue (heterograft or xenograft valve tissue). In some embodiments, valve component 100 may be a mechanical valve. For example, when valve component 100 is a biological valve, expansion of valve component 100 from a collapsed configuration to an expanded may require self-expansion of an affixed stent component 200. In contrast, a synthetic valve component 100 may be capable of self-expansion. Valve component 100 may have a shape/form (e.g., length, width, diameter, etc.) corresponding to that of the intended valve application (e.g., tricuspid, pulmonary, mitral or aortic). In FIGS. 1A and 1B, valve component 100 is a tricuspid valve with three flaps. This particular configuration may be particularly suitable, for example, for replacing a failed aortic valve. In other embodiments, valve component 100 may have any other suitable number of flaps and/or other physical characteristics (e.g., diameter, length, width, etc.)



FIG. 2A is a perspective view of stent component 200 in accordance with an embodiment of the present invention. As shown in FIG. 2B, stent component 200 houses valve component 100. In some embodiments, at least a portion of stent component 200 may be substantially cylindrical in shape. Alternatively or additionally, stent component 200 may have an indentation (e.g., annular groove) or other fixation element 202, for example, for fixing the stent in place at the implantation site. For example, when stent component 200 is part of double-stent-valve 400 (FIG. 4), fixation element 202 may matably attach to a complimentary fixation element 302 (e.g., inward annular projection, FIG. 3A) of stent component 300. When stent component 200 is part of a single-stent valve (FIG. 2B), fixation element 202 may affix to at least a portion of the failed valve. Additional embodiments of stent components that may include fixation elements are described in connection with FIGS. 6A and 8A-16.


In some embodiments of the present invention, stent component 200, like valve component 100, may be capable of at least two configurations: a first, collapsed configuration (e.g., during delivery) and a second, expanded configuration (e.g., after installation). FIG. 2A shows stent component 200 in an illustrative expanded configuration. FIG. 2C shows stent component 200 in an illustrative collapsed configuration, with the collapsed valve component 100 housed therein, for example, for delivery of both components to the implantation site at the same time. In some embodiments, stent component 200 may be made from wire or may be laser cut from a tube, sheath, or the like. Stent component 200 may include a shape-memory alloy material such as, for example, nitinol. The shape-memory alloy may allow for compression of stent component 200 (and/or valve component 100) into the first configuration for, for example, delivery through a small opening in the patient's body and expansion of stent component 200 to the second configuration during installation. Components 100 and/or 200 may be held in the collapsed configuration, for example, with a sheath or wrap. The sheath/wrapping may be removed in order to allow components 100 and/or 200 to reconfigure into the second configuration.


Valve component 100 may be secured to stent component 200 via any suitable securing mechanism or combination of securing mechanisms. For example, in one embodiment, valve component 100 may be sutured with one or more stitches to stent component 200. In another embodiment, valve component 100 may be secured to stent component 200 by way of a friction fitting. For example, valve component 100 may have a fully-expanded diameter that is slightly larger than the expanded diameter of stent component 200 such that components 100 and 200 fit securely together upon expansion of component 100 within component 200. In yet another embodiment, a hook-and-loop type (e.g., VELCRO®) fastening system may be used to secure valve component 100 to stent component 200. For example, stent component 200 may include microscopic hooks and valve component 100 may include corresponding microscopic loops (or vice-versa). This hook-and-loop fastening system may include a micro-velour material, which has been used previously for surgical applications to improve tissue in-growth. Such a hook-and-loop fastening system may allow the position of valve component 100 to be fine-tuned relative to the position of stent component 200, for example, after components 100 and 200 have been implanted within a patient's body. The hooks/loops may also facilitate blood clotting and the formation of a seal at the interface between valve component 100 and stent component 200. To avoid premature clot formation (e.g., excessive clot formation before installation is complete), anti-coagulation monitoring and/or treatment may be provided to the patient. Reliable hook-and-loop connections may still be achieved in the presence of premature clot formation, although higher activation pressure (described below) may be required. A preliminary evaluation shows that reliable hook-and-loop connections can be formed in the presence of water, jelly, liquid soap, and/or coagulating proteins. In some embodiments, such a hook-and-loop fastening system may be used, alternatively or additionally, to secure stent component 200 to stent component 300 (e.g., with the microscopic hooks attached to an exterior surface of stent component 200 and the corresponding microscopic loops attached to an interior surface of stent component 300, or vice versa).


Any suitable mechanism or combination of mechanisms (e.g., direct or indirect exertion of mechanical compression) can be used to supply the activation pressure required to cause the micro-hooks to attach to the micro-loops. For example, in some embodiments, one or more balloons may be positioned adjacent to valve component 100 and/or stent component 200 (e.g., within valve component 100) and inflated temporarily to bring the micro-hooks into contact with the micro-loops. Such balloon(s) may placed within the valve component 100 and/or stent component 200 subsequent to delivery of the stent and/or valve to the implantation site. Alternatively, in some embodiments the balloon(s) can be mounted (e.g., removably mounted) within the valve component 100 and/or stent component 200 prior to delivery of the stent and/or valve to an implantation site (e.g., prior to loading the stent and/or valve into a delivery device). The use of such balloon(s) is not limited to embodiments in which the valve and stent are affixed to one another by way of hooks/loops. Rather, such balloon(s) may be used whenever it is necessary or desirable to use the balloon(s) to aid in the expansion and/or engagement at the implantation site of the stent and/or valve (e.g., when the valve is sutured to the stent). In some embodiments, a self-expanding valve component 100 may be provided that self-expands within stent component 200 in order to cause the micro-hooks to contact the micro-loops.



FIG. 3A is a perspective view of stent component 300 in accordance with an embodiment of the present invention. As described above, stent component 300 may have a fixation element 302 (e.g., inward annular projection) that matably attaches to a complimentary fixation element 202 of stent component 200 (FIG. 2A). FIG. 4 shows an embodiment of such matable attachment, in which component 300 houses both components 100 and 200 to form double-stent-valve 400. The geometry (e.g., length, width(s), diameter(s), etc.) of stent component 300 may be particularly suited, for example, for aortic valve replacement. In other embodiments, other geometries and configurations of stent component 300 may be provided.


Stent component 300 may be secured in place at the implantation site using any suitable securing mechanism or combination of securing mechanisms. For example, in some embodiments, fixation element 302 may form a recess (e.g., exterior annular groove) for receiving at least a portion of the failed valve. In some embodiments, stent component 300 may have a diameter slightly larger than a diameter of the implantation site such that delivery and expansion of stent component 300 at the implantation site secures stent component 300 in place by way of a friction fitting. In some embodiments, stent component 300 may include one or more projections (e.g., spikes) or clasps for anchoring stent component 300 to the failed valve anchor adjacent structures) at the implantation site.



FIGS. 5A-7B illustrate embodiments of the present invention for replacing a failed artificial (e.g., biological) valve (e.g., stent-valve) introduced to a patient's body during a prior surgery. FIG. 5A is a perspective view of a failed biological valve 500 where leaflets 502 of the valve fail to close. FIG. 5B is a perspective view of the failed biological valve 500 after implantation of the stent-valve shown in FIG. 2B. As shown, failed biological valve 500 (e.g., and/or its accompanying stent) secure the new stent-valve in place at the implantation site. More particularly, fixation element 202 of the stent-valve (FIGS. 2A and 2B), which may be an annular groove forming the narrowest portion of the stent-valve, may receive the annulus of failed biological valve 500 thereby securing the stent-valve in place. In other embodiments of the present invention, at least a portion of failed biological valve 500 may be removed from the patient's body (e.g., the failed valve itself), whereas other portion(s) of the failed valve may be left behind at the implantation site (e.g., a supporting stent). In still other embodiments, the failed biological valve 500 including all of its associated component(s) may be substantially entirely removed from the implantation site prior to installation of the new stent-valve.



FIG. 6A is a perspective view of another example of a stent-valve 600 in accordance with an embodiment of the present invention. FIG. 6B is a perspective view showing a use of stent-valve 600 to replace a failed artificial (e.g., biological) valve. Stent-valve 600 includes one or more (e.g., three) locking or retaining elements 602 along an outer surface of the stent component. Each locking element 602 may include directionality such that it collapses (e.g., becomes flush with an outer surface of the stent component) upon engagement of the locking element with another surface (e.g., the interior of a catheter). When a locking element 602 protrudes from the outer surface of the stent component, a first end 604 of the locking element may be adjacent to the outer surface of the stent component, while a second end 606 of the locking component may be spaced apart from the outer surface of the stent component. When multiple locking elements 602 are provided, first ends 604 of all the locking elements may be positioned at substantially the same vertical height/position along the central axis of the stent component (e.g., albeit dispersed evenly around the perimeter of the stent component), and second ends 606 may be positioned at different vertical height(s)/position(s) than first ends 604. First end 604 may be flexible (e.g., allowing hinge-like movement in two dimensions) such that movement of the second end relative to the outer surface of the stent component does not impair the locking mechanism.


In some embodiments of the present invention, stent-valve 600 may be inserted into the interior of the failed valve in the direction of arrow 608 in FIG. 6B. When first end 604 of each locking element 602 encounters the interior diameter/annulus of the failed valve, second end 606 of the locking element may collapse toward the outer surface of the stent component. Upon second end 606 of the locking element reaching an open area of the failed valve, the second end may jut outwardly, locking stent-valve 600 in place. Thus, locking elements 602 may provide a mechanism for securing the new stent-valve in place, as an alternative to or in addition to fixation element 610 (e.g., annular groove) of the stent component for affixing stent-valve 600 to (for example) the annulus the failed valve.



FIGS. 7A and 7B show another embodiment of a stent component 700 with locking elements in accordance with the present invention. FIG. 7A shows that such a stent component can be made from, for example, a sheet of suitable material (e.g., nitinol). Referring to FIG. 7B, stent component 700 includes one or more locking elements 702 that extend radially from an outer surface of the stent component such that, for each locking element, first end 704 and second end 706 of that locking element have substantially the same vertical position/height along the central axis of the stent component. In other embodiments, such locking elements may be slightly angled, such that ends 704 and 706 of the same locking element have different relative vertical positions/heights along the central axis of the stent component. In some embodiments, a stent component may be provided that includes multiple locking elements, with each locking element having ends 704 and 706 with different angular orientations. Different locking elements 702 may have the same or different vertical positions/heights along the central axis of the stent component.



FIGS. 8A-16 show additional examples of suitable stent components for use in valve replacement in accordance with some embodiments of the present invention. These stent components may be used, for example, as part of single-stent-valves and double-stent-valves. Each of these stent components includes one or more attachment elements for removably attaching the stent component (e.g., together with an integrated valve component) to a delivery device (FIGS. 22-26). In some embodiments, these stent components may also include a fixation element (e.g., similar to fixation element 202 (FIG. 2A)) for fixing the stent component in place at the implantation site.



FIG. 8A shows a perspective view of a stent component 800 in a collapsed configuration, as well as an as-cut view of stent component 800 that illustrates details regarding its structure. FIG. 8B shows stent component 800 in an expanded configuration. Stent component 800 includes first (e.g., proximal) section 802 that includes a fixation element (e.g., annular groove), second section 804 that may follow the contour of a valve component to be housed therein, and third (e.g., distal) section 806 that includes one or more (e.g., three) attachment elements 808. In some embodiments, stent component 800 may include (for example) a lattice structure (e.g., formed from nitinol wire), for example, with section 802 having a denser population of lattice cells than section 804 and/or section 806. This may provide added support to the fixation element in section 802 and therefore increase the stability of device 800 at the implantation site. In some embodiments, stent component 800 may include only closed lattice cells in order to facilitate the recapture of stent component 800 by a delivery device when stent component 800 is in a partially-expanded configuration (described below).


In some embodiments, each of attachment elements 808 may include an opening (e.g., circular or ovular) for removably attaching stent component 800 to a complimentary element (e.g., wire, strap or hook) of a delivery device. Attachment elements 808 may allow for partial expansion of the stent component (e.g., together with an integrated valve component and/or another stent component) within a patient's body while causing the stent component to remain attached to the delivery system. For example, sections 802 and 804 (e.g., and part of section 806) of stent component 800 may expand when stent component 800 is partially released from a shaft during delivery, whereas no change may be observed to the relative positions of attachment elements 808 still constrained by the shaft (e.g., see FIG. 28 “partial release”). This may allow a surgeon to reposition and/or test the functionality of the stent-valve (or double-stent-valve) within the patient's body before finalizing deployment of the stent-valve at the implantation site. Such testing of the valve functionality may include peripheral pulse monitoring, whereby a pulse wave is measurable if the valve is functioning properly. A more reliable assessment of the stent valve function can be made with transesophageal echocardiography (TEE), intravascular ultrasound (IVUS) and/or intracardiac echocardiography (ICE). If the stent-valve malfunctions during the test (e.g., if the valve does not permit sufficient blood-flow), the stent-valve may be fully recaptured by the delivery device and retrieved from the patient's body. In other embodiments, stent component 800 may have a different lattice structure, attachment elements 808 may be reduced or enlarged in length and/or other dimension(s), and/or attachment elements 808 may be included in other location(s) relative to stent component 800 (e.g., within section 804).



FIG. 8C shows another embodiment of a stent component with integrated attachment elements 814 that are configured such that the fully expanded diameter in the region of the attachment element(s) is smaller than the diameter of the region that houses an associated valve. As shown in this example, the attachment elements project partially inwardly toward the center axis of the stent component. This may reduce the risk of injury to the patient's body (e.g., perforation of the aorta) from the attachment elements. Alternatively or additionally, this may make it easier to affix the attachment elements to a complimentary structure of the delivery device. For example, when the device is collapsed for attachment to the delivery device, the reduced diameter within the region of the attachment elements may cause the attachment elements to engage the stent holder earlier.



FIG. 8D shows yet another embodiment of a stent component in accordance with the present invention. In this embodiment, the first (proximal) section of the stent includes 27 independent, bendable elements 816, each of which may include connected and/or disconnected cell(s) which can be open and/or closed. In this embodiment, each bendable element includes a single, closed cell. In other embodiments, other number(s) and/or configuration(s) of the bendable elements may be provided. Bendable elements 816 allow for accurate positioning/securing of the proximal stent section to the geometry/topology of (for example) a calcified annulus/failed biological valve. Each element 816 can bend/adapt independently to the topology of the immediately adjacent portion of the calcified annulus/failed biological valve. Bendable elements 816 collectively form an annular groove in which the location of the bending deformation (grooved portion) for each bendable element is controlled by reducing or elongating the lengths of an attached pair of stent struts (818, 820) which act as a joint. The length of a single stent strut is shown by numeral 822. Primarily, the radial three/resistance of each bendable element 816 is influenced by the selection of angle 824 during stent manufacturing. Other design parameters such as strut thickness/width also influence the radial force. An advantage of this design is that the stent proximal section can more adequately anchor the stent in place at the implantation site independently of the stent mid section. Thus, the stent mid section can be designed to accommodate (for example) the aortic valve without any over sizing, therefore reducing the risk of valve failure due to long term mechanical stress. The stent of FIG. 8D also includes compensation element 826 (e.g., including a triangular wave portion and two elongate arms) for accommodating elongation mismatch (if any) within the stent during manufacturing and/or crimping. Contrast FIG. 8D with the embodiment shown in FIG. 8C, in which the absence of dedicated pairs of struts prevents the stent proximal section from having elements that bend independently (e.g., during implantation).



FIG. 8E shows another embodiment of a stent component in accordance with the present invention. In FIG. 8E, only about ⅓ of an as-cut view of the stent component is shown in order to more clearly show its features. Similar to the locking/retaining elements 602 shown in FIGS. 6A and 6B, the stent component shown in FIG. 8E includes a plurality of independently bendable locking elements 828 generally located within the region of the stent component referenced as region 804 in FIG. 8B. Locking elements 828 form a crown that may engage, for example, a failed biological valve or calcified native annulus from the outflow side. The stent component in FIG. 8E also includes fixation element 830 (e.g., annular groove). In FIG. 8E, locking elements 828 are shown as being positioned at substantially the same position/height along the central axis of the stent component. In other embodiments, different locking elements 828 may have the same or different vertical positions/heights along the central axis of the stent component similar to, for example, the stent shown in FIG. 7B. Having different positions/heights for at least some of locking elements 828 may facilitate engagement with, for example, native valves of different sizes (e.g., a thin native valve which can be engaged by locking elements separated by a small distance or a thick native valve which can only be engaged by more distantly spaced locking elements).



FIG. 8F shows another embodiment of a stent component in accordance with the present invention. In FIG. 8F, only about ⅓ of an as-cut view of the stent component is shown in order to more clearly show its features. FIG. 8F includes a Dacron pocket 832 for housing a valve component, where Dacron pocket 832 is sutured along the valve free edge 834. As shown, the valve component within pocket 832 is housed more closely to attachment element(s) 836, which are similar to attachment elements 808 in FIG. 8B, in the embodiment of FIG. 8F than in the embodiment shown in FIG. 9C. A middle inverted U-shaped strut 838 is slid into Dacron pocket 832. The valve/pocket is sutured to an outer inverted U-shaped strut 840. Inner U-shaped strut 842 is positioned outside Dacron pocket 832 and serves as a skid during loading/releasing/recapturing of the implant with a delivery device by reducing the friction forces between Dacron pocket 832 and the outer sheath. Inner U-shaped strut 842 may also be sutured to Dacron pocket 832. In some embodiments, Dacron pocket 832 may be closed with further stitching 844. Although the bottom portion of the stent is not shown in FIG. 8F, in some embodiments it may include, for example, a fixation element (e.g., annular groove) similar to fixation element 802 in FIG. 8B.



FIGS. 9A-9C show another example of a stent component 900 with integrated attachment element(s) 902 in accordance with an embodiment of the present invention. FIG. 9A shows a perspective view of stent component 900 in a collapsed configuration, as well as an as-cut view of stent component 900 that illustrates details regarding its structure. FIG. 9B is a perspective view of stent component 900 in an expanded configuration. FIG. 9C shows stent component 900 (with an integrated valve component) positioned beside a ruler to show its size (e.g., about 4 centimeters). As shown, each of attachment elements 902 includes a circular or ovular opening attached to stent component 900 by two supporting elements 904 (e.g., wires). In turn, each pair of supporting elements 904 attaches to a stem 906 (e.g., commissural post) within the lattice structure. In contrast, each of the attachment elements 808 in FIG. 8B attaches to stent component 800 by a single supporting element 810, and each supporting element 810 is attached to a stem 812. All of the stent components shown in FIGS. 8A-16 include three stems, although it will be understood that other suitable numbers of stems or no stems at all (e.g., FIG. 2A) may be provided in accordance with some embodiments of the present invention. Stent component 900 also includes a fixation element 908, which may be substantially similar to fixation element 202 (FIG. 2A). In the embodiment of FIG. 9C, the valve component is sutured around the circumference of its annulus. Bach of the three leaflets of the valve component is also spot-sutured to the stent to permit valve functionality. The locations of the sutures may be selected in order to permit elongation of the stent during crimping without damaging the valve or suture. For example, the inflow of stent (e.g., within region 802 shown in FIG. 8B) may be covered on its inner side with a cloth (e.g., mesh). The cloth and valve component may be sutured to the stent (e.g., using a running and/or interrupted technique) in the region adjacent to the annular groove (e.g., along the border of stent sections 802 and 804 in FIG. 8B). Some excess cloth on the inflow side may be folded over onto the exterior side of the stent and sutured together with the valve component in the vicinity of (e.g., further towards section 804) the previous suturing location. The commissures of the valve component may also be attached to the corresponding stent posts, which may have previously been covered with cloth (e.g., Dacron). Alternatively, pericardium or other suitable material can be used to cover the stent component. In some embodiments, the valve component may be a porcine valve component which may be harvested as such or assembled from various donors in order to have an optimal match between three cusps. Bovine and equine valves may also be used that are made from pericardium. Other suitable sources of valve components can also be used.



FIGS. 10A-10B show yet another example of a stent component 1000 with integrated attachment element(s) 1002 in accordance with an embodiment of the present invention. FIG. 10A shows a perspective view of stent component 1000 in a collapsed configuration, as well as an as-cut view of stent component 1000 that illustrates details regarding its structure. FIG. 10B is a perspective view of stent component 1000 in an expanded configuration. As shown, at least one pair (e.g., all pairs) of attachment elements 1002 are attached to one another with a bracing element 1004. Each bracing element 1004 may attach on one end to a first attachment element 1002 and on the other end to a second attachment element 1002. In some embodiments, the bracing element(s) 1004 may include a wire shaped like a triangular wave. When all attachment elements 1002 include a bracing element 1004, collectively the bracing elements 1004 may form a circle around the perimeter of stent component 1000. Stent component 1000 may be substantially the same as stent component 800 (FIG. 8B) in all other respects.



FIGS. 11-16 show additional examples of stent components with integrated attachment element(s) in accordance with some embodiments of the present invention. Each of FIGS. 11-16 includes a perspective view of a stent component in a collapsed configuration, as well as an as-cut view of the stent component that illustrates details regarding its structure. The following description summarizes various features of the stent components shown in FIGS. 11-16. Additional structural features of the embodiments shown in FIGS. 8A-16 will be apparent to one of ordinary skill in the art from the drawings.



FIG. 11 shows a stent component that includes shorter supporting element(s) for attaching to a corresponding number of ovular/circular attachment element(s) (i.e., shorter in comparison to supporting elements 810 of FIG. 8B). The stem(s) in FIG. 11 for attaching to the supporting elements may be substantially the same as stems 906 in FIG. 9B.



FIG. 12 shows a stent component that includes two supporting elements for attaching to each ovular/circular attachment element. Each pair of supporting elements attaches to a stem such that collectively the supporting elements and stem form a second ovular/circular opening, for example, for added support and/or for use as an additional or alternative attachment element. The stem(s) in FIG. 12 may be substantially the same as stems 906 in FIG. 9B.



FIG. 13 shows a stent component that includes non-circular/ovular attachment components such as, for example, wires, hooks, straps, or a combination thereof for ratably attaching to a complimentary element of a delivery device (e.g., a circular or ovular opening). The stent component in FIG. 13 also includes an increased number of attachment elements (e.g., six) when compared to the number of attachment elements (e.g., three) of stent component 900 (FIGS. 9A and 9B). In FIG. 13, the attachment elements attach directly to the stems of the stent component, two attachment elements per stem. The stem(s) in FIG. 13 may be substantially the same as stems 906 in FIG. 9B.



FIG. 14 shows a stent component that replaces the wire/hook attachment elements in FIG. 13 with long, narrow openings (e.g., long and narrow in comparison to attachment elements 902 of FIG. 9A). The stem(s) in FIG. 14 may be substantially the same as stems 906 in FIG. 9B.



FIG. 15 shows a stent component with a modified lattice structure, including a modified stem structure. The stent component in FIG. 15 also includes circular/ovular attachment elements, where each attachment element is attached to a stem by two supporting elements. Each pair of supporting elements and corresponding stem may form a second circular/ovular opening, in a manner similar to the supporting element/stem configuration shown in FIG. 12.



FIG. 16 shows a stent component with attachment elements modified relative to the attachment elements shown in FIG. 15. Each attachment element in FIG. 16 includes a wire (e.g., a “U”-shaped wire), with both ends of the wire attaching directly to the same stem such that the attachment element/stem configuration forms a substantially ovular/circular opening. The stem(s) in FIG. 16 may be substantially the same as the stems shown in FIG. 15.



FIGS. 17/18, 19 and 20 show additional examples of double-stent-valves in accordance with some embodiments of the present invention. Single-stent valve 1700 of FIG. 17 includes stent 1702 and valve component 1704. FIG. 1.8 shows a double-stent valve that includes stent-valve 1700 and positioning stent 1802, which may be attached together by way of (for example) an annular groove and corresponding annular recess. Stent component 1802 may be covered with, for example, pericardium in order to prevent paravalvular leaking. The double-stent-valve of FIG. 18 may have a generally cylindrical shape that is suitable for, for example, pulmonary and/or aortic applications.


Now referring to FIGS. 19 and 20, FIG. 19 shows a double-stent-valve with first stent 1902, second stent 1904, and valve component 1906. FIG. 20 shows a double-stent-valve with first stent 2002, second stent 2004, and valve component 2006. Again, the positioning stents in FIGS. 19 and 20 may be covered (e.g., with pericardium) in order to prevent paravalvular leaking. The stents of FIGS. 19 and 20 may be suitable for, for example, pulmonary valve replacement (e.g., in the presence of an aneurysm that creates a deformation and where there is no suitable rim for placement of a grooved stent-valve). More particularly, with respect to pulmonary valve applications, many candidates for pulmonary valve replacement have an aneurysm there or a funnel-type configuration at the inflow or at the outflow. Thus, the first stent 1902 or 2002 can adapt to this funnel-type pulmonary artery configuration and provide the round orifice for securing the stent-valve (1904, 1906) or (2004, 2006). In some embodiments, a double-stent-valve similar to the double-stent-valve of FIG. 20 may be provided that is suitable for mitral and/or tricuspid valve applications, where the positioning stent has a reduced height and an oval configuration that provides a round rim for attachment to a groove of a stent-valve (alternatively, a hook-loop fastening system can be used). Alternatively or additionally, the positioning stent may have independently bendable elements that provide a secure fit at the implantation site. Additional structural features of the embodiments shown in FIGS. 17-20 and details regarding their use for valve replacement will be apparent to one of ordinary skill in the art from the drawings.



FIG. 21A shows another example of a stent-valve 2100 in accordance with some embodiments of the present invention. The embodiment shown in FIG. 21A may be suitable for, for example, mitral valve replacement. Stent-valve 2100 may be assembled from a stent component and a valve component outside the patient's body prior to delivery of stent-valve 2100 to an implantation site. Stent-valve 2100 may be a self-expanding stent-valve adapted for replacement of the mitral valve. As shown, stent-valve 2100 may have a shape similar to an opposed double crown. Stent-valve 2100 may include a porcine pulmonary valve 2102 sutured into a Dacron conduit (prosthetic tube), with two self-expanding nitinol Z-stents 2104 and 2106 sutured on the external surface of the prosthesis in such a way to create two self-expanding crowns. The self-expanding stent-valve may be loaded for delivery into a Teflon sheath, or other suitable delivery system. In this embodiment, Dacron is used to cover the stent, although in other embodiments other materials such as Teflon, silicon, pericardium, etc. may be used. In one surgical approach, an incision of 1 centimeter may be made on the left atrium, controlled by purse string sutures. The Teflon sheath with loaded stent may be pushed along a guide wire (the atrium having been punctured with a needle and the guide wire inserted) until the middle of stent-valve reaches the mitral annulus. Then, the sheath may be pulled back to deploy the ventricular side first, followed by total removal of the sheath to expose the atrial side. Additional details regarding stent-valve 2100 and a surgical approach for delivering it to an implantation site are described in Liang Ma et al., “Double-crowned valved stents for off-pump mitral valve replacement”, European Journal of Cardio-Thoracic Surgery 28:194-199, Jun. 13, 2005, which is incorporated by reference herein in its entirety.



FIGS. 21B-E show views of a double-conical stent in accordance with some embodiments of the present invention. Referring to FIGS. 21B and 21C, the double-conical stent may include a substantially cylindrical stent 2108 carrying a valve 2110 as well as two substantially conical stents (2112, 2114) affixed/attached to stent 2108 (e.g., with VELCRO®, suture(s), friction fitting(s), other suitable affixing mechanism(s), or a combination thereof). FIG. 21D shows a cross-section of the double-conical stent shown in FIGS. 21B and 21C. In other embodiments, at least one of stents 2112 and 2114 may have a crown-shape with protruding spikes formed from open or closed, cells or Z-stents. The first and second additional stents (2112, 2114) may collectively form a fixation element 2116 (FIG. 21C; e.g., annular groove) similar to fixation element 202 shown in FIG. 2A. Fixation element 2116 may allow for fixation, for example, in an orifice of a failed valve which is of similar size as the stent 2108 carrying valve component 2110 or to an anchoring stent with a complimentary annular projection. In some embodiments, stents 2112 and 2114 (and optionally stent 2108) may be replaced with a single stent in a double-conical configuration (e.g., the two cones connected by a continuous region in the area of fixation element 2116). An advantage to using separate stent(s) for the cones/fixation element is that the mechanical stresses of the cones/fixation element (e.g., first and second stents 2112 and 2114) can be at least partially separated from stent 2108 containing the valve. In some embodiments, at least the additional stent or portion thereof positioned closer to the tip of the delivery system (e.g., stent 2112) may be recapturable by the delivery system. To facilitate such recapturing, the additional stent may be formed in a pyramid or wing cross-sectional configuration 2118 (FIG. 21E). In some embodiments, the wing(s) or spikes of stent 2112 (and/or 2114) may be formed at various positions/heights along a central axis of stent 2108 similar to, for example, the stent shown in FIG. 7B. Having different positions/heights for at least some of the wings or spikes may facilitate engagement with, for example, native valves of different sizes. In some embodiments, the stents shown in FIGS. 21B-21E (e.g., stent 2108) may include at least one attachment element for removably attaching to a delivery device, similar to attachment elements 808 shown in FIG. 8B.



FIGS. 22A-26C show examples of delivery systems for delivering stent-valves (e.g., single-stent-valves or double-stent-valves) to an implantation site in accordance with some embodiments of the present invention. In some embodiments, the present invention provides a minimally-invasive surgical approach whereby the surgery is performed on a beating heart without the need for an open-chest cavity and heart-lung bypass. The heart may be penetrated, for example, trans-apically through a relatively small opening in the patient's body. For example, to replace a failed aortic valve, the patient's body may be penetrated through an intercostal space (e.g., fifth intercostal space), which is a region between two ribs. From this access point, the left ventricle may be penetrated at the apex of the heart. In one approach, a suitable stent-valve delivery system may initially penetrate the body/heart (e.g., delivery system 2600 (FIGS. 26A-26C) which includes an integrated introducer). In another approach, a separate introducer sheath may be used. A guide wire (hollow needle, catheter, stiff guide wire, etc.) may be inserted through the introducer to guide delivery of, for example, stent component(s), a valve component, and/or other devices (e.g., an occluder device). In some embodiments, transluminal, transatrial, or transventricular access approaches may be used for, for example, tricuspid and/or mitral valve replacement. The right ventricle of the heart may also be accessed for pulmonary valve replacement. This is in contrast to other surgical approaches that deliver replacement valves via open-chest cavities. Moreover, as described in greater detail below in connection with FIGS. 22A-28C, delivery systems according to some embodiments of the present invention release the proximal portion of the stent-valve first, which may allow for testing of the valve when the body is accessed, for example, trans-parietally. Upon a successful test, the distal portion of the stent-valve may be released. This contrasts with stent delivery systems that initially release the distal portions of their associated stents.



FIGS. 22A-22D show a delivery system 2200 that includes two concentrically-arranged parts, a first assembly (including elements 2202-2210) and a second assembly (including elements 2216-2230). More particularly, the first assembly may include tip 2202 at the distal end of the delivery system (with a guide wire passing through the length of the delivery system and out the tip), inner shaft 2204, outer sheath 2206, metal shaft 2208, and push handle 2210. The second assembly may include outer shaft (distal) 2216, tapered outer shaft connector 2218, outer shaft (proximal) 2220, stent holder 2222, kink protector 2224, hold handle connector 2226, hold handle cup 2228, and O-ring 2230. As shown, push handle 2210 is located at the proximal end of the delivery system. In FIGS. 22A and 22B, outer shaft 2220 has been split along its length to allow the components of delivery system 2200 to be shown in greater detail. Valve 2212 and stent(s) 2214 form a third assembly that can be, for example, loaded and crimped between the first and second assemblies.


With respect to the first assembly, inner shaft 2204 functions as a lumen for a guide wire. Tip 2202 is bonded at its distal end. As used herein, bonding refers to any suitable securing/fastening mechanism such as, for example, adhesive bonding using cyanoacrylate or UV-curing adhesives or thermal bonding/welding using heat energy to melt the components to be assembled. Outer sheath 2206 may be bonded to the proximal section of tip 2202 and may constrain the stent-valve (2212, 2214). Outer sheath 2206 may be perforated to allow device flushing via hold handle 2210. The proximal part of the first assembly may be reinforced with metal shaft 2208 and may end into the push handle with a luer connector for guide wire lumen flushing.


With respect to the second assembly, stent holder 2222 may be bonded distally on distal outer shaft 2216. FIG. 22D shows a perspective view better illustrating the arrangement between the stent-valve (2212, 2214) and stent holder 2222. Distal outer shaft 2216 may be bonded proximally to proximal outer shaft 2220 via tapered connector 2218. Proximal outer shaft 2220 may be bonded via kink protector 2224 to the hold handle assembly, which may include hold handle connector 2226 and hold handle cup 2228. The hold handle assembly may compress O-ring 2230 for sealing delivery system 2200. A luer connector may allow for device flushing. The flush mechanism may be used to remove trapped air from the delivery system prior to its insertion into the body. Alternatively or additionally, the flush mechanism may be used to cool down a stent (e.g., nitinol stent) prior to its release and/or recapture by flushing the stent with a cold saline solution. Cooling down the stent may cause a reversible modification of its structure, thus reducing its Young-modulus and therefore the stent radial force and the forces necessary for its delivery and recapture.


Delivery system 2200 is said to be in an open position (FIG. 22C) when (for example) push handle 2210 contacts the hold handle cup 2228. In the open position, the stent-valve (2212, 2214) may detach from stent holder 2222 and fully expand at an implantation site. Prior to delivery system 2200 reaching the open position, the stent-valve may be crimped onto delivery system 2200 by means of a crimping machine (for example) and held in place by stent holder 2222. Stent holder 2222 may affix to the attachment elements of the stents shown in FIGS. 8A-16. The crimped stent-valve may be maintained in a collapsed configuration by pulling back the first assembly thus covering the attachment components/stent holder 2222 with outer sheath 2206. Once the outer sheath 2206 is removed such that it no longer constrains the attachment components, the stent-valve may automatically detach from stent holder 2222 due to the self-expanding property of the stent-valve. Delivery system 2200 is said to be in a closed position (FIGS. 22A and 22B) when outer sheath 2206 fully encompasses the stent-valve (2212, 2214) such that no expansion of the stent-valve occurs.


Delivery system 2200 is said to be in a partially open position when (for example) push handle 2210 is partially pushed towards hold handle cup 2228. In this partially open position, the stent-valve (2212, 2214) is deployed proximally and still attached distally to stent holder 2222 via the attachment elements. This allows for an accurate implantation/positioning of the stent-valve. For example, the stent-valve may be partially released proximal to the intended implantation site and slightly pushed distally until resistance is felt. Final release of the stent-valve (2212, 2214) may occur by completely pushing the push handle towards hold handle cup 2228 so that delivery system 2200 reaches the open position. Such a partially-open position is illustrated in FIG. 28B. In some embodiments, an imaging mechanism may be used to determine whether the stent-valve is positioned correctly at the implantation site. For example, roadmapping under fluoroscopy can be realized with angiography, intra-vascular ultrasound (IVUS), intra-cardiac echocardiography (ICE), trans-esophageal echocardiography (TEE) or other mechanism(s) or combination thereof, which imaging mechanism may be at least partially integral to or separate from the delivery system.


Upon implantation of the stent-valve (2212, 2214), delivery system 2200 may revert to the closed position prior to retrieval from the patient's body, for example, by holding the first assembly and pushing the second assembly distally towards tip 2202/outer sheath 2206. In other embodiments, the handle for releasing the stent-valve may comprise a screw mechanism for transferring a rotational movement of the handle into a translational movement of the outer sheath. This type of release system may allow for stepwise, more accurate stent release and recapturing as well as a reduction of the release force felt by the surgeon.



FIGS. 23A-23D show another example of a delivery system 2300 in accordance with an embodiment of the present invention. Delivery system 2300 may be substantially similar to delivery system 2200 (FIG. 22) (e.g., closed position, FIGS. 23A and 23B; opened position, FIG. 23C), except delivery system 2300 may additionally include one or more folded balloons 2302 (e.g., proximal to the stent-valve). Unless otherwise indicated, like features in FIGS. 23A-23D correspond to the same reference numerals in FIGS. 22A-22D, although the reference numerals have not been reproduced in FIGS. 23A-23D to avoid over complicating the drawings. The same applies to the stent delivery systems shown in FIGS. 24A-D, FIGS. 25A-C, and FIGS. 26A-C. Balloon 2302 may be inflated/deflated via an additional lumen in proximal outer shaft 2304, for example, to anchor the stent-valve (e.g., a non-self-expanding stent-valve) in place at an implantation site. FIG. 23D shows a cross section “A-A” of the lumen structure shown in FIG. 23C. The lumen structure includes 5-lumen tubing 2306 and inner shaft 2308. In other embodiments, other structures for lumen tubing 2306 may be used (e.g., bi-lumen tubing where the second lumen is used for balloon inflation and deflation). Delivery system 2300 may also include access mechanism 2310 for balloon inflation/deflation, which may allow connection of a syringe or inflation device to inflate/deflate a balloon. Alternatively or additionally, tubing with an attached stop-cock may be connected to access mechanism 2310.



FIGS. 24A-24D show another example of a delivery system 2400 in accordance with an embodiment of the present invention. In delivery system 2400, proximal outer shaft 2402 may have an increased diameter in comparison to the diameter of proximal outer shaft 2220 (FIG. 22). The increased diameter may reduce bleeding when the delivery system is used without an introducer. Alternatively, when an introducer is used, the increased diameter may match the internal diameter of the introducer which, in turn, may depend on the outer diameter of the outer sheath. Having no gap between the introducer and delivery system may reduce the risk of a potential retrieval issue of the delivery system through the introducer due to entrapped blood. Accordingly, delivery system 2400 may include a floating tube 2404 that fills the gap between the inner and outer assemblies, thus reducing the risk of the inner assembly kinking under compression which would result in higher friction forces within the delivery system during stent recapturing. Delivery system 2400 may be substantially similar to delivery system 2200 in all other respects (e.g., closed position, FIGS. 24A and 24B; opened position, FIG. 24C).



FIGS. 25A-C show another example of a delivery system 2500 in accordance with an embodiment of the present invention. Delivery system 2500 may include one or more balloons 2536 distal to the stent-valve. Having the balloon(s) distal to the stent-valve avoids having to introduce the delivery system deeper into the body (e.g., into the ascending aorta) in order to perform dilation, thereby reducing risk of injury to the body and improving device handling (e.g., no bending of rigid device over the aortic arch). Balloon(s) 2536 can be used for, for example, valvuloplasty prior to stent-valve implantation and/or post-dilation of the implanted stent-valve to improve the anchoring of the stent. FIGS. 25B and 25C show the balloon(s) 2536 in closed and open positions, respectively.


The first assembly of delivery system 2500 may include tip 2502, inner balloon shaft 2504, outer sheath 2506, and floating tube 2508. The second assembly may include inner shaft (distal) 2510, stent holder transition 2512, stent holder 2514, sleeve 2516, tapered transition shaft connector 2518, and outer shaft (proximal) 2520. The handle assembly may include hold handle connector 2522, hold handle cup 2524, O-ring 2526, metal shaft 2528, and push handle 2530. The balloon assembly may include outer shaft 2532, inner shaft 2534, balloon 2536, and Y connector 2538.



FIGS. 26A-C show another example of a delivery system 2600 in accordance with an embodiment of the present invention. Delivery system 2600 may include an integrated introducer 2602, which may be an additional assembly that houses the second assembly. The outer sheath of the delivery system is shown as 2604. Introducer 2602 may include a connecting line 2606, a stopcock 2608 and a housing 2610 for the sealing membrane 2612. Stopcock 2608 may serve as an access point for, for example, a syringe containing fluid (e.g., saline). Connecting line 2606 may serve to transport the fluid from the syringe to the inner lumen of the introducer, and sealing membrane 2612 may seal the introducer from the outside environment. Upon stent-valve implantation, the components of delivery system 2600 (e.g., first assembly and second assembly) other than introducer 2602 may be retrieved through the introducer. Then, another medical device such as, for example, a closure device may be introduced through introducer 2602. Examples of closure devices are described below in connection with FIGS. 29A-33B. As another example, intravascular ultrasound (IVUS) equipment (e.g., mini-probe) may be introduced through introducer 2602. Delivery system 2600 may be substantially similar to delivery system 2200 in all other respects.



FIG. 27 is a flowchart 2700 of illustrative stages involved in replacing a failed (e.g., native or artificial) valve in accordance with some embodiments of the present invention. FIGS. 28A-28C illustrate (without limitation) various stages referenced in the flowchart of FIG. 27. At stage 2702, a stent-valve (e.g., single-stent-valve or double-stent-valve) may be removably attached to a delivery system. For example, one or more attachment elements of a stent component (e.g., attachment elements 808, FIG. 8B) may be affixed to a stent holder of the delivery device (e.g., stent holder 2222, FIG. 22). A collapsing element (e.g., outer sheath 2206, FIG. 22) may be placed over the attachment elements/stent holder to maintain the stent-valve in a collapsed configuration and attached to the delivery system.


At stage 2704, the stent-valve may be delivered to an implantation site in a collapsed configuration. For example, FIG. 28A (“introduction” and “positioning”) shows that stent-valve 2802, while still attached to the delivery system via stent holder 2804 and fully contained within outer sheath 2806, may be introduced to a patient's body along guide wire 2808 so that tip 2810 of the delivery system passes through failed valve 2812. The delivery system may be manipulated forwards and/or backwards, for example, until the stent-valve is believed to be positioned correctly.


At stage 2706, the stent-valve may be partially expanded, for example, to determine (stage 2708) whether the stent-valve is in fact positioned correctly and/or to test (stage 2710) whether the stent-valve is functioning properly. For example, FIG. 28A (“partial release”) shows that outer sheath 2806 may be partially removed from proximal section 2814 of the stent-valve, while attachment elements 2816 of the stent-valve are still constrained by outer sheath 2806 onto stent holder 2804.


At stage 2712, when the stent-valve is positioned correctly at the implantation site and/or the stent-valve is functioning properly, the stent-valve may be detached from the delivery system in order to cause the stent-valve to expand to its fully-expanded configuration. For example, FIG. 28C (“final release”) shows that, upon removal of attachment elements 2816 and stent holder 2804 from within outer sheath 2806, attachment elements 2816 of stent-valve 2802 may detach from stent holder 2804 automatically (or in response to balloon inflation in other embodiments) thereby causing the stent-valve to expand to its fully-expanded configuration. The second assembly of the delivery device may then be reunited with the first assembly/outer sheath and removed from the patient's body. For example, FIG. 28C (“delivery device retrieval”) shows that the second assembly 2818 may be passed through replacement stent-valve 2802 towards the distal end of the stent-valve. Then, the reunited second assembly 2818 and first assembly/outer sheath 2806 may be passed through stent-valve 2802 again in the proximal direction before exiting the patient's body.


When the stent-valve is not positioned correctly (stage 2708), at stage 2714 the stent-valve may be reverted to the collapsed configuration and repositioned within the patient's body. An illustration of this scenario is illustrated in FIG. 28B (“stent recapturing/repositioning”), in which outer sheath 2806 is slid in the proximal direction over proximal section 2814 of the stent-valve in order to recapture the stent-valve. The stent-valve is then repositioned and released such that fixation element 2820 of the stent-valve receives an annulus 2822 of the failed valve. Similarly, when the stent-valve malfunctions in response to a test (stage 2710), at stage 2716 the stent-valve may be reverted to the collapsed configuration and removed from the patient's body.



FIGS. 29A-33B show illustrative embodiments of guide wire compatible closure (occluder) devices for sealing access orifices and associated surgical instruments in accordance with some embodiments of the present invention. Such an occluder may repair, for example, a cardiac access orifice (e.g., ventricular orifice) used for valve replacement. The occluder may be introduced to a patient's body after a replacement valve has been implanted (or removed due to malfunction or complication during installation). Embodiments of the present invention address shortcomings with conventional closure devices, such as the looseness of their fit. Conventional closure devices also lack a central lumen, which renders them incompatible with guide wire delivery systems.



FIGS. 29A and 29B are side and perspective views of an occluder 2900 in accordance with some embodiments of the present invention. Occluder 2900 may include stainless steel wire, nitinol, textile fibers, fills, biocompatible materials, and/or other suitable materials which allow the device to perform as intended. In some embodiments, at least a portion of occluder 2900 may be fitted/filled with a flexible but tight material such as, for example, a membrane or foam. Occluder 2900 may or may not include a skeleton (e.g., lattice structure with a filling material) and/or sealing membranes. Such a skeleton may comprise nitinol, stainless steel, magnesium, nylon, polyester, polypropylene, polydioxanon, other suitable material(s), or a combination thereof. The filling material may include, for example, polyester, polyurethane, gelatin, other suitable material(s), or a combination thereof. When occluder 2900 includes a sealing mechanism, such a mechanism may be flexible such that it does not interfere with the expanding or collapsing of occluder 2900 (described below) according to some embodiments of the present invention.


Top portion 2902 of occluder 2900 may be positioned on the luminal side of an access orifice, while bottom portion 2904 may be positioned outside the access orifice. Guide wire compatibility may be achieved through a central channel within occluder 2900. The central channel may include at its bottom end, for example, a hollow screw device 2906 for attaching occluder 2900 to a catheter during delivery and detaching the occluder from the catheter upon installation within the access orifice. In other embodiments, occluder 2900 may be attached/detached to a catheter by a thin wall that can be twisted off, by a connection mechanism in the shape of a hook, or by a mechanism that detaches via galvanic corrosion or the like.


Occluder 2900 may include a channel sealing mechanism 2908 such as, for example, a self-sealing membrane and/or foam. In some embodiments, channel sealing mechanism 2908 may include a valve (e.g., one or more plastic leaflets). Channel sealing mechanism 2908 may prevent blood-flow through the occluder from top/luminal portion 2902 to bottom portion 2904 after the occluder is installed within the access orifice. During delivery, the positioning of a guide wire through channel sealing mechanism 2908 (and the central channel) may or may not substantially or entirely prevent blood-flow through channel sealing mechanism 2908. In some embodiments, mechanism 2908 may rely, at least in part, on blood clotting in order to form a seal. In some embodiments, mechanism 2908 (including a membrane, an iris mechanism, or collapsible walls) may form the seal (with or without assistance from blood clotting).


In some embodiments, top/luminal portion 2902 of occluder 2900 may be made from different material(s) (or the same material(s) but having different characteristics) than the material(s) used for bottom/outer portion 2904. For example, bottom outer portion 2904 made be made from a coarser or more porous material than top/luminal portion 2902 to facilitate the formation of scar tissue on the outer portion. Bioabsorbable material(s) may also be used for portion 2902 and/or 2904 of occluder 2900 (e.g., magnesium and/or polydioxanone for a skeleton portion and/or polydioxanone, polyhydroxybutyrate, and/or gelatin as a filler).



FIG. 30 shows a perspective view of a guide wire 3000 for guiding the delivery of occluder 2900 to the access orifice. Guide wire 3000 may be the same guide wire used, for example, far a valve replacement surgery involving one of the delivery systems shown in FIGS. 22A-26C. FIG. 31 shows a perspective view of a threaded catheter 3100 for attaching to occluder 2900 during delivery and detaching from occluder 2900 once installation of the occluder is complete. As shown in FIGS. 32A and 32B, screw device 2906 of occluder 2900 may attach to threaded catheter 3100, and occluder 2900 may be loaded into second catheter 3202. For example, second catheter 3202 may be part of the delivery system (e.g., FIG. 26A-C) used for delivery of a replacement valve. Guide wire 3000 may extend through both the central channel of occlude 2900 and second catheter 3200. Guide wire 3000 may also be removable and reinsertable. FIG. 32B shows that the occluder can be partially unloaded by moving catheter 3100 relative to catheter 3202. Advantageously, if occluder 2900 is not positioned correctly upon partial release, it can be reloaded into catheter 3202 and relocated to the proper location within the access orifice without excessive manipulation of occluder 2900 and/or the associated delivery instruments.



FIGS. 33A and 33B illustrate side and perspective views of occluder 2900 in an expanded configuration within an access orifice in accordance with an embodiment of the present invention. Preferably, luminal/top portion 2902 and outer/bottom portion 2904 of occluder 2900 cover the access orifice completely. The central channel is also preferably sealed by, for example, a self-sealing membrane and/or sealing foam 2908.


Thus it is seen that stent-valves (e.g., single-stent-valves and double-stent-valves) and associated methods and systems for surgery are provided. Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made without departing from the spirit and scope of the invention as defined by the claims. Other aspects, advantages, and modifications are considered to be within the scope of the following claims. The claims presented are representative of the inventions disclosed herein. Other, unclaimed inventions are also contemplated. The inventors reserve the right to pursue such inventions in later claims.

Claims
  • 1. A method for implanting a stent-valve at an implantation site for cardiac valve replacement, comprising the steps of: providing a stent-valve and a delivery device, the delivery device including a stent-holder and an outer-sheath;removably attaching the stent-valve to the delivery device by way of the stent-holder and the outer sheath, wherein: the stent-valve comprises a valve component, and a stent component including at least two integral attachment elements provided therewith,the stent component and the valve component configured with a collapsed configuration for delivery and an expanded configuration after implantation,the at least two attachment elements are matably attached to the stent-holder, such that the stent-valve is held in position with respect to the delivery device by the stent-holder,in a closed position, the outer sheath encompasses the stent-valve and constrains expansion of the stent-valve, andthe outer sheath is configured for distal movement relative to the stent holder in order to transition from the closed position, to a partially-open position, to an open position;delivering the stent-valve to the implantation site in the collapsed condition;partially expanding the stent-valve while maintaining attachment of the at least two attachment elements to the stent-holder, such that the stent-holder holds the stent-valve in position with respect to the delivery device;determining whether the partially expanded stent-valve is positioned correctly at the implantation site;wherein upon the determination being positive, allowing the at least two attachment elements to detach from the stent-holder to cause the stent-valve to expand from the partially expanded configuration to the expanded configuration; andwherein upon the determination being negative, returning the stent-valve to the collapsed configuration and repositioning the stent-valve at the implantation site.
  • 2. The method of claim 1, wherein the at least two attachment elements are matably attached to a complimentary structure of the stent-holder, such that the stent-valve is held in position with respect to the delivery device by the stent-holder.
  • 3. The method of claim 2, wherein allowing the at least two attachment elements to detach from the stent-holder comprise allowing the at least two attachment elements to detach from mateable engagement with the complimentary structure of the stent-holder.
  • 4. The method of claim 2, wherein the stent-holder comprises a radial extending structure positioned towards the distal end of the delivery device.
  • 5. The method of claim 4, wherein the complimentary structure comprises the radial extending structure, and wherein matably attached comprises removably attached to the radial extending structure.
  • 6. The method of claim 1, wherein the stent-holder comprises a body positioned towards the distal end of the delivery device.
  • 7. The method of claim 6, wherein matably attached comprises removably attached to the stent-holder body.
  • 8. The method of claim 1, wherein the stent-component further comprises a lattice structure comprising closed cells configured to facilitate recapture of the stent-valve when partially expanded.
  • 9. The method of claim 8, wherein matably attached comprises removably attached to the stent-holder.
  • 10. The method of claim 1, wherein the at least two attachment elements are interconnected by bracing elements in a circular configuration, each bracing element comprising a plurality of peaks between the attachment elements.
  • 11. The method of claim 10, wherein matably attached comprises removably attached to the stent-holder.
CROSS-REFERENCE TO RELATED APPLICATIONS

The present application claims priority to U.S. application Ser. No. 14/471,731, filed Aug. 28, 2014, and entitled “Stent-Valves for Valve Replacement and Associated Methods and Systems for Surgery,” which in turn claims priority to U.S. application Ser. No. 13/433,910, filed Mar. 29, 2012, and entitled “Stent-Valves for Valve Replacement and Associated Methods and Systems for Surgery,” which in turn claims priority to U.S. application Ser. No. 11/700,922, filed Dec. 21, 2006, and entitled “Stent-Valves for Valve Replacement and Associated Methods and Systems for Surgery,” which in turn claims the benefit of U.S. Provisional Patent Application No. 60/753,071, filed Dec. 22, 2005, U.S. Provisional Patent Application No. 60/755,590, filed Dec. 29, 2005, and U.S. Provisional Patent Application No. 60/843,181, filed Sep. 7, 2006. The present application incorporates herein by reference the disclosures of each of the above-referenced applications in their entireties.

US Referenced Citations (572)
Number Name Date Kind
3755823 Hancock Sep 1973 A
4106129 Carpentier et al. Aug 1978 A
4191218 Clark et al. Mar 1980 A
4297749 Davis et al. Nov 1981 A
4470157 Love Sep 1984 A
4922905 Strecker May 1990 A
5002566 Carpentier et al. Mar 1991 A
5061277 Carpentier et al. Oct 1991 A
5078720 Burton et al. Jan 1992 A
5094661 Levy et al. Mar 1992 A
5104407 Lam et al. Apr 1992 A
5163955 Love et al. Nov 1992 A
5192301 Kamiya et al. Mar 1993 A
5197979 Quintero et al. Mar 1993 A
5272909 Nguyen et al. Dec 1993 A
5279612 Eberhardt Jan 1994 A
5327774 Nguyen et al. Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5336258 Quintero et al. Aug 1994 A
5344442 Deac Sep 1994 A
5352240 Ross Oct 1994 A
5354330 Hanson et al. Oct 1994 A
5368608 Levy et al. Nov 1994 A
5411552 Andersen et al. May 1995 A
5456713 Chuter Oct 1995 A
5480424 Cox Jan 1996 A
5487760 Villafana Jan 1996 A
5499995 Teirstein Mar 1996 A
5500015 Deac Mar 1996 A
5509930 Love Apr 1996 A
5540712 Kleshinski et al. Jul 1996 A
5549666 Hata et al. Aug 1996 A
5554185 Block et al. Sep 1996 A
5569274 Rapacki et al. Oct 1996 A
5571174 Love et al. Nov 1996 A
5571215 Sterman et al. Nov 1996 A
5595571 Jaffe et al. Jan 1997 A
5609626 Quijano et al. Mar 1997 A
5613982 Goldstein Mar 1997 A
5632778 Goldstein May 1997 A
5653749 Love et al. Aug 1997 A
5662703 Yurek et al. Sep 1997 A
5674298 Levy et al. Oct 1997 A
5679112 Levy et al. Oct 1997 A
5682906 Sterman et al. Nov 1997 A
5683451 Lenker et al. Nov 1997 A
5697972 Kim et al. Dec 1997 A
5713950 Cox Feb 1998 A
5713951 Garrison et al. Feb 1998 A
5713953 Vallana et al. Feb 1998 A
5718725 Sterman et al. Feb 1998 A
5728151 Garrison et al. Mar 1998 A
5746765 Kleshinski et al. May 1998 A
5746775 Levy et al. May 1998 A
5755777 Chuter May 1998 A
5769882 Fogarty et al. Jun 1998 A
5797960 Stevens et al. Aug 1998 A
5799661 Boyd et al. Sep 1998 A
5807327 Green et al. Sep 1998 A
5814016 Valley et al. Sep 1998 A
5817126 Imran Oct 1998 A
5823956 Roth et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824061 Quijano et al. Oct 1998 A
5824063 Cox Oct 1998 A
5824080 Lamuraglia Oct 1998 A
5829447 Stevens et al. Nov 1998 A
5840081 Andersen et al. Nov 1998 A
5841382 Walden et al. Nov 1998 A
5843181 Jaffe et al. Dec 1998 A
5855210 Sterman et al. Jan 1999 A
5855600 Alt Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5861028 Angell Jan 1999 A
5876434 Flomenblit et al. Mar 1999 A
5880242 Hu et al. Mar 1999 A
5899936 Goldstein May 1999 A
5924424 Stevens et al. Jul 1999 A
5928281 Huynh et al. Jul 1999 A
5935163 Gabbay Aug 1999 A
5938697 Killion et al. Aug 1999 A
5957949 Leonhardt Sep 1999 A
5976174 Ruiz Nov 1999 A
5980455 Daniel et al. Nov 1999 A
5980533 Holman Nov 1999 A
5997573 Quijano et al. Dec 1999 A
6001126 Nguyen-Thien-Nhon Dec 1999 A
6010531 Donlon et al. Jan 2000 A
6027476 Sterman et al. Feb 2000 A
6029671 Stevens et al. Feb 2000 A
6077297 Robinson et al. Jun 2000 A
6079414 Roth Jun 2000 A
6083257 Taylor et al. Jul 2000 A
6092529 Cox Jul 2000 A
6093530 McIlroy et al. Jul 2000 A
6102944 Huynh et al. Aug 2000 A
6110191 Dehdashtian et al. Aug 2000 A
6110201 Quijano et al. Aug 2000 A
6117169 Moe Sep 2000 A
6125852 Stevens et al. Oct 2000 A
6126685 Lenker et al. Oct 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6177514 Pathak et al. Jan 2001 B1
6182664 Cosgrove Feb 2001 B1
6183481 Lee et al. Feb 2001 B1
6196230 Hall et al. Mar 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6214036 Letendre et al. Apr 2001 B1
6214055 Simionescu et al. Apr 2001 B1
6231602 Carpentier et al. May 2001 B1
6245105 Nguyen et al. Jun 2001 B1
6254564 Wilk et al. Jul 2001 B1
6254636 Peredo Jul 2001 B1
6269819 Oz et al. Aug 2001 B1
6270526 Cox Aug 2001 B1
6283127 Sterman et al. Sep 2001 B1
6283995 Moe et al. Sep 2001 B1
6287334 Moll et al. Sep 2001 B1
6287338 Sarnowski et al. Sep 2001 B1
6287339 Vazquez et al. Sep 2001 B1
6311693 Sterman et al. Nov 2001 B1
6325067 Sterman et al. Dec 2001 B1
6331189 Wolinsky et al. Dec 2001 B1
6338740 Carpentier Jan 2002 B1
6342070 Nguyen-Thien-Nhon Jan 2002 B1
6344044 Fulkerson et al. Feb 2002 B1
6346074 Roth Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6378221 Ekholm, Jr. et al. Apr 2002 B1
6379372 Dehdashtian et al. Apr 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6379740 Rinaldi et al. Apr 2002 B1
6391538 Vyavahare et al. May 2002 B1
6401720 Stevens et al. Jun 2002 B1
6406493 Tu et al. Jun 2002 B1
6409759 Peredo Jun 2002 B1
6425916 Garrison et al. Jul 2002 B1
6451054 Stevens Sep 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6471723 Ashworth et al. Oct 2002 B1
6478819 Moe Nov 2002 B2
6494211 Boyd et al. Dec 2002 B1
6494897 Sterman et al. Dec 2002 B2
6508833 Pavcnik et al. Jan 2003 B2
6509145 Torrianni Jan 2003 B1
6521179 Girardot et al. Feb 2003 B1
6530952 Vesely Mar 2003 B2
6533807 Wolinsky et al. Mar 2003 B2
6537310 Palmaz et al. Mar 2003 B1
6540782 Snyders Apr 2003 B1
6558318 Daniel et al. May 2003 B1
6558417 Peredo May 2003 B2
6558418 Carpentier et al. May 2003 B2
6562069 Cai et al. May 2003 B2
6564805 Garrison et al. May 2003 B2
6569196 Vesely May 2003 B1
6572642 Rinaldi et al. Jun 2003 B2
6572652 Shaknovich Jun 2003 B2
6582462 Andersen et al. Jun 2003 B1
6585766 Huynh et al. Jul 2003 B1
6589279 Anderson et al. Jul 2003 B1
6605112 Moll et al. Aug 2003 B1
6613069 Boyd Sep 2003 B2
6613079 Wolinsky et al. Sep 2003 B1
6613086 Moe et al. Sep 2003 B1
6635085 Caffey et al. Oct 2003 B1
6651672 Roth Nov 2003 B2
6652555 VanTassel et al. Nov 2003 B1
6652578 Bailey et al. Nov 2003 B2
6673109 Cox Jan 2004 B2
6679268 Stevens et al. Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6692512 Jang Feb 2004 B2
6695865 Boyle et al. Feb 2004 B2
6695875 Steller et al. Feb 2004 B2
6719787 Cox Apr 2004 B2
6719788 Cox Apr 2004 B2
6719789 Cox Apr 2004 B2
6723122 Yang et al. Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6733513 Boyle et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6736827 McAndrew et al. May 2004 B1
6736845 Marquez et al. May 2004 B2
6736846 Cox May 2004 B2
6755855 Yurek et al. Jun 2004 B2
6767362 Schreck Jul 2004 B2
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6802319 Stevens et al. Oct 2004 B2
6805711 Quijano et al. Oct 2004 B2
6808529 Fulkerson Oct 2004 B2
6820676 Palmaz et al. Nov 2004 B2
6821297 Snyders Nov 2004 B2
6824970 Vyavahare et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6830585 Artof et al. Dec 2004 B1
6830586 Quijano et al. Dec 2004 B2
6849085 Marton Feb 2005 B2
6861211 Levy et al. Mar 2005 B2
6872226 Cali et al. Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6881199 Wilk et al. Apr 2005 B2
6893460 Spenser et al. May 2005 B2
6899704 Sterman et al. May 2005 B2
6908481 Cribier Jun 2005 B2
6911043 Myers et al. Jun 2005 B2
6936066 Palmaz et al. Aug 2005 B2
6939359 Tu et al. Sep 2005 B2
6942682 Vrba et al. Sep 2005 B2
6955175 Stevens et al. Oct 2005 B2
6974464 Quijano et al. Dec 2005 B2
6974474 Pavcnik et al. Dec 2005 B2
6979350 Moll et al. Dec 2005 B2
7014655 Barbarash et al. Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7018408 Bailey et al. Mar 2006 B2
7022134 Quijano et al. Apr 2006 B1
7025773 Gittings et al. Apr 2006 B2
7025780 Gabbay Apr 2006 B2
7028692 Sterman et al. Apr 2006 B2
7037333 Myers et al. May 2006 B2
7041132 Quijano et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7048757 Shaknovich May 2006 B2
7050276 Nishiyama May 2006 B2
7078163 Torrianni Jul 2006 B2
7081132 Cook et al. Jul 2006 B2
7101396 Artof et al. Sep 2006 B2
7118585 Addis Oct 2006 B2
7137184 Schreck Nov 2006 B2
7141064 Scott et al. Nov 2006 B2
7163556 Xie et al. Jan 2007 B2
7179290 Cao Feb 2007 B2
7189259 Simionescu et al. Mar 2007 B2
7195641 Palmaz et al. Mar 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7214344 Carpentier et al. May 2007 B2
7217287 Wilson et al. May 2007 B2
7235092 Banas et al. Jun 2007 B2
7238200 Lee et al. Jul 2007 B2
7252682 Seguin Aug 2007 B2
7276078 Spenser et al. Oct 2007 B2
7276084 Yang et al. Oct 2007 B2
7285130 Austin Oct 2007 B2
7314449 Pfeiffer et al. Jan 2008 B2
7314485 Mathis Jan 2008 B2
7314880 Chang et al. Jan 2008 B2
7316712 Peredo Jan 2008 B2
7317005 Hoekstra et al. Jan 2008 B2
7317942 Brown Jan 2008 B2
7317950 Lee Jan 2008 B2
7318278 Zhang et al. Jan 2008 B2
7318998 Goldstein et al. Jan 2008 B2
7319096 Malm et al. Jan 2008 B2
7320692 Bender et al. Jan 2008 B1
7320704 Lashinski et al. Jan 2008 B2
7320705 Quintessenza Jan 2008 B2
7320706 Al-Najjar Jan 2008 B2
7322932 Xie et al. Jan 2008 B2
7326174 Cox et al. Feb 2008 B2
7326219 Mowry et al. Feb 2008 B2
7327862 Murphy et al. Feb 2008 B2
7329278 Seguin et al. Feb 2008 B2
7329279 Haug et al. Feb 2008 B2
7329280 Bolling et al. Feb 2008 B2
7329777 Harter et al. Feb 2008 B2
7331991 Kheradvar et al. Feb 2008 B2
7331993 White Feb 2008 B2
7333643 Murphy et al. Feb 2008 B2
7335158 Taylor Feb 2008 B2
7335213 Hyde et al. Feb 2008 B1
7335490 Van Gilst et al. Feb 2008 B2
7338484 Schoon et al. Mar 2008 B2
7361189 Case et al. Apr 2008 B2
7361190 Shaoulian et al. Apr 2008 B2
7364588 Mathis et al. Apr 2008 B2
7371258 Woo et al. May 2008 B2
7374571 Pease et al. May 2008 B2
7377895 Spence et al. May 2008 B2
7377938 Sarac et al. May 2008 B2
7377940 Ryan et al. May 2008 B2
7381210 Zarbatany et al. Jun 2008 B2
7381218 Schreck Jun 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7381220 Macoviak et al. Jun 2008 B2
7389874 Quest et al. Jun 2008 B2
7390325 Wang et al. Jun 2008 B2
7393358 Malewicz Jul 2008 B2
7393360 Spenser et al. Jul 2008 B2
7396364 Moaddeb et al. Jul 2008 B2
7399315 Iobbi Jul 2008 B2
7402171 Osborne et al. Jul 2008 B2
7404792 Spence et al. Jul 2008 B2
7404793 Lau et al. Jul 2008 B2
7410499 Bicer Aug 2008 B2
7412274 Mejia Aug 2008 B2
7412290 Janke et al. Aug 2008 B2
7415861 Sokel Aug 2008 B2
7416530 Turner et al. Aug 2008 B2
7422603 Lane Sep 2008 B2
7422606 Ung-Chhun et al. Sep 2008 B2
7423032 Ozaki et al. Sep 2008 B2
7426413 Balczewski et al. Sep 2008 B2
7427279 Frazier et al. Sep 2008 B2
7427287 Turovskiy et al. Sep 2008 B2
7427291 Liddicoat et al. Sep 2008 B2
7430448 Zimmer et al. Sep 2008 B1
7431691 Wilk Oct 2008 B1
7431733 Knight Oct 2008 B2
7435059 Smith et al. Oct 2008 B2
7435257 Lashinski et al. Oct 2008 B2
7445630 Lashinski et al. Nov 2008 B2
7445632 McGuckin, Jr. et al. Nov 2008 B2
7452371 Pavcnik et al. Nov 2008 B2
7455689 Johnson Nov 2008 B2
7462156 Mitrev Dec 2008 B2
7462184 Worley et al. Dec 2008 B2
7462191 Spenser et al. Dec 2008 B2
7468050 Kantrowitz Dec 2008 B1
7470284 Lambrecht et al. Dec 2008 B2
7470285 Nugent et al. Dec 2008 B2
7473275 Marquez Jan 2009 B2
7476196 Spence et al. Jan 2009 B2
7476199 Spence et al. Jan 2009 B2
7476200 Tal Jan 2009 B2
7481838 Carpentier et al. Jan 2009 B2
7485088 Murphy et al. Feb 2009 B2
7485143 Webler et al. Feb 2009 B2
7488346 Navia Feb 2009 B2
7497824 Taylor Mar 2009 B2
7500949 Gottlieb et al. Mar 2009 B2
7500989 Solem et al. Mar 2009 B2
7503929 Johnson et al. Mar 2009 B2
7503930 Sharkawy et al. Mar 2009 B2
7507199 Wang et al. Mar 2009 B2
7510572 Gabbay Mar 2009 B2
7510575 Spenser et al. Mar 2009 B2
7510577 Moaddeb et al. Mar 2009 B2
7513863 Bolling et al. Apr 2009 B2
7513909 Lane et al. Apr 2009 B2
7522950 Fuimaono et al. Apr 2009 B2
7530253 Spenser et al. May 2009 B2
7534261 Friedman May 2009 B2
7556646 Yang et al. Jul 2009 B2
7578828 Gittings et al. Aug 2009 B2
7585321 Cribier Sep 2009 B2
7591848 Allen Sep 2009 B2
7618446 Andersen et al. Nov 2009 B2
7625403 Krivoruchko Dec 2009 B2
7632296 Malewicz Dec 2009 B2
7682390 Seguin Mar 2010 B2
7780726 Seguin Aug 2010 B2
7823267 Bolduc Nov 2010 B2
7837727 Goetz et al. Nov 2010 B2
7846203 Cribier Dec 2010 B2
7846204 Letac et al. Dec 2010 B2
7896915 Guyenot et al. Mar 2011 B2
7914575 Guyenot et al. Mar 2011 B2
7947075 Goetz et al. May 2011 B2
7959672 Salahieh et al. Jun 2011 B2
8002825 Letac et al. Aug 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8057540 Letac et al. Nov 2011 B2
8092518 Schreck Jan 2012 B2
8092520 Quadri Jan 2012 B2
8603159 Seguin et al. Dec 2013 B2
8628571 Hacohen et al. Jan 2014 B1
8647381 Essinger et al. Feb 2014 B2
8845721 Braido et al. Sep 2014 B2
20010007956 Letac et al. Jul 2001 A1
20020032481 Gabbay Mar 2002 A1
20020123790 White et al. Sep 2002 A1
20020161377 Rabkin Oct 2002 A1
20020177894 Acosta et al. Nov 2002 A1
20030023300 Bailey et al. Jan 2003 A1
20030027332 Lafrance et al. Feb 2003 A1
20030028213 Thill et al. Feb 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030036795 Andersen et al. Feb 2003 A1
20030040771 Hyodoh Feb 2003 A1
20030040792 Gabbay Feb 2003 A1
20030042186 Boyle Mar 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030065386 Weadock Apr 2003 A1
20030139796 Sequin et al. Jul 2003 A1
20030139803 Sequin et al. Jul 2003 A1
20030149476 Damm et al. Aug 2003 A1
20040004926 Maeda Jan 2004 A1
20040006380 Buck et al. Jan 2004 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040044361 Frazier et al. Mar 2004 A1
20040044400 Cheng et al. Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040059407 Escamilla et al. Mar 2004 A1
20040073289 Hartley Apr 2004 A1
20040093060 Seguin et al. May 2004 A1
20040093063 Wright et al. May 2004 A1
20040106976 Bailey et al. Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040153145 Simionescu et al. Aug 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040193244 Hartley et al. Sep 2004 A1
20040210301 Obermiller Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040236411 Sarac et al. Nov 2004 A1
20040254594 Alfaro Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20050009000 Wilhelm et al. Jan 2005 A1
20050033220 Wilk et al. Feb 2005 A1
20050043759 Chanduszko Feb 2005 A1
20050049692 Numamoto et al. Mar 2005 A1
20050070794 Deal et al. Mar 2005 A1
20050070957 Das Mar 2005 A1
20050075725 Rowe Apr 2005 A1
20050075776 Cho Apr 2005 A1
20050096726 Sequin et al. May 2005 A1
20050096736 Osse et al. May 2005 A1
20050098547 Cali et al. May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050119728 Sarac Jun 2005 A1
20050119736 Zilla et al. Jun 2005 A1
20050137681 Shoemaker et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137693 Haug et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050143804 Haverkost Jun 2005 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050149166 Schaeffer et al. Jul 2005 A1
20050150775 Zhang et al. Jul 2005 A1
20050171597 Boatman et al. Aug 2005 A1
20050171598 Schaeffer Aug 2005 A1
20050182483 Osborne et al. Aug 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050222668 Schaeffer et al. Oct 2005 A1
20050222674 Paine Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050267523 Devellian et al. Dec 2005 A1
20050267560 Bates Dec 2005 A1
20050283231 Haug et al. Dec 2005 A1
20050288706 Widomski et al. Dec 2005 A1
20060004442 Spenser et al. Jan 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060047343 Ovialt et al. Mar 2006 A1
20060058864 Schaeffer et al. Mar 2006 A1
20060074484 Huber Apr 2006 A1
20060111770 Pavcnik et al. May 2006 A1
20060122692 Gilad et al. Jun 2006 A1
20060142846 Pavcnik et al. Jun 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060155366 LaDuca et al. Jul 2006 A1
20060161248 Case et al. Jul 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060190070 Dieck et al. Aug 2006 A1
20060193885 Leonard Neethling et al. Aug 2006 A1
20060210597 Hiles Sep 2006 A1
20060224183 Freudenthal Oct 2006 A1
20060229718 Marquez Oct 2006 A1
20060246584 Covelli Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060265056 Nguyen et al. Nov 2006 A1
20060270958 George Nov 2006 A1
20060287717 Rowe Dec 2006 A1
20060287719 Rowe et al. Dec 2006 A1
20060290027 O'Connor et al. Dec 2006 A1
20060293745 Carpentier et al. Dec 2006 A1
20070005129 Damm et al. Jan 2007 A1
20070005131 Taylor Jan 2007 A1
20070005132 Simionescu et al. Jan 2007 A1
20070020248 Everaerts et al. Jan 2007 A1
20070021826 Case et al. Jan 2007 A1
20070027535 Purdy et al. Feb 2007 A1
20070038291 Case et al. Feb 2007 A1
20070038295 Case et al. Feb 2007 A1
20070043435 Seguin et al. Feb 2007 A1
20070050014 Johnson Mar 2007 A1
20070060998 Butterwick et al. Mar 2007 A1
20070061002 Paul et al. Mar 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20070093887 Case et al. Apr 2007 A1
20070100435 Case et al. May 2007 A1
20070100440 Figulla et al. May 2007 A1
20070112422 Dehdashtian May 2007 A1
20070123700 Ueda et al. May 2007 A1
20070123979 Perier et al. May 2007 A1
20070142906 Figulla et al. Jun 2007 A1
20070142907 Moaddeb et al. Jun 2007 A1
20070162103 Case et al. Jul 2007 A1
20070173932 Cali et al. Jul 2007 A1
20070179592 Schaeffer Aug 2007 A1
20070179600 Vardi Aug 2007 A1
20070198097 Zegdi Aug 2007 A1
20070203576 Lee et al. Aug 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070239265 Birdsall Oct 2007 A1
20070239269 Dolan et al. Oct 2007 A1
20070239271 Nguyen Oct 2007 A1
20070244543 Mitchell Oct 2007 A1
20070244546 Francis Oct 2007 A1
20070244551 Stobie Oct 2007 A1
20070260327 Case et al. Nov 2007 A1
20070282436 Pinchuk Dec 2007 A1
20070288087 Fearnot et al. Dec 2007 A1
20080021546 Patz et al. Jan 2008 A1
20080033534 Cook et al. Feb 2008 A1
20080065011 Marchand et al. Mar 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071362 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071368 Tuval et al. Mar 2008 A1
20080077234 Styrc Mar 2008 A1
20080077236 Letac et al. Mar 2008 A1
20080086205 Gordy et al. Apr 2008 A1
20080097586 Pavcnik et al. Apr 2008 A1
20080102439 Tian et al. May 2008 A1
20080125859 Salahieh et al. May 2008 A1
20080133003 Seguin et al. Jun 2008 A1
20080140189 Nguyen et al. Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080161909 Kheradvar et al. Jul 2008 A1
20080177381 Navia et al. Jul 2008 A1
20080195199 Kheradvar et al. Aug 2008 A1
20080200977 Paul et al. Aug 2008 A1
20080208327 Rowe Aug 2008 A1
20080215143 Seguin Sep 2008 A1
20080228263 Ryan Sep 2008 A1
20080234814 Salahieh et al. Sep 2008 A1
20080255660 Guyenot et al. Oct 2008 A1
20080262602 Wilk et al. Oct 2008 A1
20080269878 Iobbi Oct 2008 A1
20080275549 Rowe Nov 2008 A1
20080275550 Kheradvar et al. Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090164006 Seguin et al. Jun 2009 A1
20090171432 Von Segesser et al. Jul 2009 A1
20090171447 Von Segesser et al. Jul 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090287299 Tabor et al. Nov 2009 A1
20100168839 Braido et al. Jul 2010 A1
20100239917 Lee et al. Sep 2010 A1
20100249915 Zhang Sep 2010 A1
20100249916 Zhang Sep 2010 A1
20100249918 Zhang Sep 2010 A1
20110022157 Essinger et al. Jan 2011 A1
20110029066 Gilad et al. Feb 2011 A1
20110040374 Goetz et al. Feb 2011 A1
20110224780 Tabor et al. Sep 2011 A1
20120022633 Olson Jan 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120116496 Chuter et al. May 2012 A1
20120123529 Levi et al. May 2012 A1
20120172982 Stacchino et al. Jul 2012 A1
20120303116 Gorman, III et al. Nov 2012 A1
20140012368 Sugimoto Jan 2014 A1
20140316518 Kheradvar Oct 2014 A1
Foreign Referenced Citations (170)
Number Date Country
2006328896 Jun 2007 AU
2007294199 Mar 2008 AU
2009200985 Apr 2009 AU
2634358 Jun 2007 CA
2657839 Mar 2008 CA
2659690 Mar 2008 CA
19546692 Jun 1997 DE
20003874 UI Jun 2000 DE
19857887 Jul 2000 DE
10121210 Nov 2002 DE
19546692 Nov 2002 DE
10335948 Feb 2005 DE
10010074 Apr 2005 DE
102005003632 Aug 2006 DE
102005051849 May 2007 DE
202007005491 Jul 2007 DE
0084395 Jul 1983 EP
0515324 Nov 1992 EP
0592410 Apr 1994 EP
0657147 Jun 1995 EP
0696447 Feb 1996 EP
0778775 Jan 1999 EP
0928615 Jul 1999 EP
0943302 Sep 1999 EP
1893132 Mar 2001 EP
1093771 Apr 2001 EP
1158937 Dec 2001 EP
0729364 Jan 2002 EP
1164976 Jan 2002 EP
0971649 Dec 2002 EP
1262201 Dec 2002 EP
1264582 Dec 2002 EP
1017868 Sep 2003 EP
1354569 Oct 2003 EP
1041943 Mar 2004 EP
1401359 Mar 2004 EP
1255510 Apr 2004 EP
1452153 Sep 2004 EP
0987998 Oct 2004 EP
1087727 Nov 2004 EP
1233731 Dec 2004 EP
1253875 Apr 2005 EP
1251803 Jun 2005 EP
1267753 Oct 2005 EP
1598031 Nov 2005 EP
1690515 Aug 2006 EP
1251805 Mar 2007 EP
1251797 Nov 2007 EP
1878407 Jan 2008 EP
1886649 Feb 2008 EP
1900343 Mar 2008 EP
1435878 Apr 2008 EP
1968491 Sep 2008 EP
1980220 Oct 2008 EP
1994913 Nov 2008 EP
2000115 Dec 2008 EP
1255510 Mar 2009 EP
2033593 Mar 2009 EP
2047824 Apr 2009 EP
2059192 May 2009 EP
2074964 Jul 2009 EP
1441672 Sep 2011 EP
1551274 Dec 2014 EP
2874812 Mar 2006 FR
2433700 Dec 2007 GB
2440809 Aug 2011 GB
2003523262 Aug 2003 JP
2003524504 Aug 2003 JP
2004267750 Sep 2004 JP
2007296375 Nov 2007 JP
4904362 Mar 2012 JP
1990009102 Aug 1990 WO
1995011055 Apr 1995 WO
1998029057 Jul 1998 WO
1999053987 Oct 1999 WO
2000002503 Jan 2000 WO
2000015148 Mar 2000 WO
2000025702 May 2000 WO
2000028922 May 2000 WO
2000047139 Aug 2000 WO
2000053122 Sep 2000 WO
2001035870 May 2001 WO
2001049213 Jul 2001 WO
2001054625 Aug 2001 WO
2001058503 Aug 2001 WO
2001062189 Aug 2001 WO
2000047139 Sep 2001 WO
2002036048 May 2002 WO
2002058745 Aug 2002 WO
2002067782 Sep 2002 WO
2002076349 Oct 2002 WO
2002100301 Dec 2002 WO
2002102286 Dec 2002 WO
2003003949 Jan 2003 WO
2003007795 Jan 2003 WO
2003009785 Feb 2003 WO
2003011195 Feb 2003 WO
2003028592 Apr 2003 WO
2003030776 Apr 2003 WO
2003047468 Jun 2003 WO
2003063729 Aug 2003 WO
2003079928 Oct 2003 WO
2003096935 Nov 2003 WO
2004004597 Jan 2004 WO
2004016200 Feb 2004 WO
2004016201 Feb 2004 WO
2004019825 Mar 2004 WO
2004026117 Apr 2004 WO
2004026173 Apr 2004 WO
2004028399 Apr 2004 WO
2004043301 May 2004 WO
2004082527 Sep 2004 WO
2004082528 Sep 2004 WO
2004096100 Nov 2004 WO
2005021063 Mar 2005 WO
2005034812 Apr 2005 WO
2005062980 Jul 2005 WO
2005070343 Aug 2005 WO
2005072654 Aug 2005 WO
2005102015 Nov 2005 WO
2006058163 Jun 2006 WO
2006068944 Jun 2006 WO
2006076890 Jul 2006 WO
2006083763 Aug 2006 WO
2006086135 Aug 2006 WO
2006086736 Aug 2006 WO
2006102063 Sep 2006 WO
2006108090 Oct 2006 WO
2006124649 Nov 2006 WO
2006127756 Nov 2006 WO
2006127765 Nov 2006 WO
2006132948 Dec 2006 WO
2007047488 Apr 2007 WO
2007047945 Apr 2007 WO
2007059252 May 2007 WO
2006086736 Jun 2007 WO
2007071436 Jun 2007 WO
2007098232 Aug 2007 WO
2007120543 Oct 2007 WO
2007071436 Nov 2007 WO
2007071436 Jan 2008 WO
2008028569 Mar 2008 WO
2008035337 Mar 2008 WO
2008040555 Apr 2008 WO
2008070442 Jun 2008 WO
2008070797 Jun 2008 WO
2008079962 Jul 2008 WO
2008101083 Aug 2008 WO
2008125153 Oct 2008 WO
2008138584 Nov 2008 WO
2008150529 Dec 2008 WO
2009024859 Feb 2009 WO
2009029199 Mar 2009 WO
2009042196 Apr 2009 WO
2009045334 Apr 2009 WO
2009045338 Apr 2009 WO
2009053497 Apr 2009 WO
2009061389 May 2009 WO
2009091509 Jul 2009 WO
2010045238 Apr 2010 WO
2010045297 Apr 2010 WO
2010049160 May 2010 WO
2010083558 Jul 2010 WO
2010098857 Sep 2010 WO
2011051043 May 2011 WO
2011057087 May 2011 WO
2012002228 Jan 2012 WO
2013033791 Mar 2013 WO
2013134214 Sep 2013 WO
2014072439 May 2014 WO
Non-Patent Literature Citations (40)
Entry
Akins et al. “Risk of Preoperative Valve Replacement for Failed Mitral and Aortic Bioprostheses”, Ann Thorac Surg (1998), 65:1545-52.
Australian Examination Report, Application No. AU 2009200985, dated Mar. 4, 2010.
Dewey et al., “Transapical aortic valve implantation: an animal feasibility study”, The annals of thoracic surgery, (2006): 82:110-116.
European Examination Report, Application No. EP07818037.9, dated Aug. 11, 2009.
European Search Report, Application No. EP09154935.2, dated May 29, 2009.
Examination Report, Application No. EP06841127.1, dated Feb. 6, 2009.
Examination Report, dated Mar. 28, 2014, for European Patent Application No. 08806901.8.
Examination Search Report, dated Oct. 30, 2014, for Canadian Application No. 2,703,665.
Hijazi et al., “Transcatheter Valve Repair” Taylor & Francis, 2006, p. 165-186.
Huber et al. “Direct Access Valve Replacement (DAVR)—are we entering a new era in cardiac surgery?” European Journal of Cardio-Thoracic Surgery, p. 380-385, Jan. 19, 2006.
Huber et al. “Direct-Access Valve Replacement: A Novel Approach for Off-Pump Valve Implantation Using Valved Stents”, Journal of the American College of Cardiology, vol. 46, No. 2, Jul. 19, 2005, p. 366-370.
International Preliminary Report on Patentability, Application No. PCT/EP 2007/07413, dated Mar. 10, 2009.
International Preliminary Report on Patentability, dated May 8, 2012, for International Application No. PCT/EP2010/063306.
International Preliminary Report, Application No. PCT/EP2006/012455, dated Jun. 24, 2008.
International Search Report and Written Opinion, dated Nov. 17, 2010, for International Application No. PCT/EP2010/063306.
International Search Report for International Application No. PCT/EP20081064558, date of completion of report, dated Mar. 18, 2009 and Written Opinion of the International Search Authority for International Application No. PCT/EP2008/064558.
International Search Report for PCT/EP2006/012455, dated Sep. 27, 2007.
IPRP for PCT/EP2007/007413, issued Mar. 10, 2009.
IPRP issued Mar. 26, 2013 for PCT/EP2011/066677.
IPRP issued May 8, 2012 for PCT/EP2010/063306.
IRPR for PCT/EP2010/057798, issued Dec. 6, 2011.
IRPR for PCT/IB2008/002180, issued Feb. 24, 2010.
ISR & WO for PCT/IB2008/002180, mailed Apr. 15, 2009.
ISR for PCT/EP2007/007413, mailed Jan. 28, 2008.
ISR for PCT/EP2010/057798, mailed Sep. 12, 2010.
ISR for PCT/EP2010/063306.
ISR mailed Apr. 17, 2014 for PCT/EP2013/073318.
ISR mailed Feb. 17, 2012 for PCT/EP2011/066677.
Lichtenstein et al. “Transapical Transcatheter Aortic Valve Implantation in Humans: Initial Clinical Experience”, Circulation, American Heart Association vol. 114; Jul. 31, 2006, p. 591-596.
Lichtenstein, Samuel V., “Closed heart surgery: Back to the future” The Journal of Thoracic and Cardiovascular Surgery, vol. 131, No. 5, 2006, p. 941-943.
Liu et al. “Effect of Fiber Orientation on the Stress Distribution within a Leaflet of a Polymer Composite Heart Valve in the Closed Position” Journal of Biomechanics. 2007 (40): 10991106.
Ma et al., “Double-crowned valved stents for off-pump mitral valve replacement”, European Journal of Cardio-Thoracic Surgery (2005), 28:194-199.
Mack, M.J., “Minimally invasive cardiac surgery”, Surg Endosc, (2006) 20:S488-S492.
Moazami et al. “Transluminal Aortic Valve Placement: a Fesibility Study with a Newly Designed Collapsible Aortic Valve”, ASAIO Journal, vol. 42; 1996.
Office Action, dated Nov. 7, 2014, for Canadian Application No. 2,703,665.
Partial International Search Report for International Application No. PCT/EP2014/055044, filed Mar. 13, 2014.
Pawelec-Wojtalk, “Closure of left ventricle perforation with the use of muscular VSD occulder”, European Journal of Cardio-Thoracic Surgery (2005), 27:714-716.
Walther et al., “Transapical approach for sutureless stent-fixed aortic valve implantation: experimental results”, European Journal of Cardiao-thoriacic Surgery 29 (2006), 703-708.
Webb et al. “Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery”, Circulation, American Heart Association, vol. 113, Feb. 6, 2006, p. 842-850.
Weerasinghe et al., “First Redo Heart Valve Replacement: A 10-Year Analysis”, Circulation (1999), 99:655-658.
Related Publications (1)
Number Date Country
20170189178 A1 Jul 2017 US
Provisional Applications (3)
Number Date Country
60843181 Sep 2006 US
60755590 Dec 2005 US
60753071 Dec 2005 US
Divisions (1)
Number Date Country
Parent 11700922 Dec 2006 US
Child 13433910 US
Continuations (2)
Number Date Country
Parent 14471731 Aug 2014 US
Child 15409320 US
Parent 13433910 Mar 2012 US
Child 14471731 US